Days	Activities	Detail

Day 1	Orientation	Briefing on pharmacy operation and services

		Discussion about the objective of the session

		Daily work schedule, including learning clinical skills and responding to symptoms

Day 2	Observation	Pharmacy layout

		Arrangement of drugs in pharmacy (outlet and store)

		Types of medicines available

		Requirements for medication storage

Day 3	Store management	Storage of drugs according to their volume of use

		First-in/first-out method

Day 4 and day 5	Pharmaceutical care for the community	Management of chronic and long-term health problems though pharmacy

		Responding to symptoms in community pharmacy

		Dealing with special health issues

		Proper information about family planning methods

		Health screening

Day 6	Counselling skills	Basic counselling skills

		Counselling for stigmatized patients

		Use of pharmacological and non-pharmacological approaches during counselling

Day 7	Practical skills	Use of medical devices

		Applying methods of physical examination

Day 8	Business plan	Drug selection criteria and drug procurement activities

		Inventory management

		Break-even point analysis

		Legal procedure for establishing a community pharmacy

Day 9	Waste management	Handling of damaged and expired drugs

		Disposal of wastage

Day 10	Medicine information source	Use of available information sources in pharmacy

		Development of informational material by the pharmacy such as leaflets, booklets, and other materials for educational purposes

Day 11	ADR reporting and pharmacovigilance	Determination of ADR by various assessment scales

		Reporting of ADR to regional pharmacovigilance center

Day 12	Future prospects	Potential for community pharmacy-managed services in the Nepalese context

Days

Day 1

Day 2

Day 3

Day 4 and day 5

Day 6

Day 7

Day 8

Day 9

Day 10

Day 11

Day 12

Activities	Detail

Orientation	Briefing on pharmacy operation and services

	Discussion about the objective of the session

	Daily work schedule, including learning clinical skills and responding to symptoms

Observation	Pharmacy layout

	Arrangement of drugs in pharmacy (outlet and store)

	Types of medicines available

	Requirements for medication storage

Store management	Storage of drugs according to their volume of use

	First-in/first-out method

Pharmaceutical care for the community	Management of chronic and long-term health problems though pharmacy

	Responding to symptoms in community pharmacy

	Dealing with special health issues

	Proper information about family planning methods

	Health screening

Counselling skills	Basic counselling skills

	Counselling for stigmatized patients

	Use of pharmacological and non-pharmacological approaches during counselling

Practical skills	Use of medical devices

	Applying methods of physical examination

Business plan	Drug selection criteria and drug procurement activities

	Inventory management

	Break-even point analysis

	Legal procedure for establishing a community pharmacy

Waste management	Handling of damaged and expired drugs

	Disposal of wastage

Medicine information source	Use of available information sources in pharmacy

	Development of informational material by the pharmacy such as leaflets, booklets, and other materials for educational purposes

ADR reporting and pharmacovigilance	Determination of ADR by various assessment scales

	Reporting of ADR to regional pharmacovigilance center

Future prospects	Potential for community pharmacy-managed services in the Nepalese context


Variable	Diabetes Patients (n=218)	Non-Diabetes (n=734)	P value

Operative time (min) (mean±SD)	434±81	422±76	0.014

Aortic cross clamp time (min) (mean±SD)	82±25	83±30	0.351

No. of coronary grafts (%)			0.143

One	3.7	4.1

Two	16.5	19.6

Three	79.8	75.5

≥Four 	0	0.8

Variable	Diabetes Patients (n=218)	Non-Diabetes (n=734)	P value

One	3.7	4.1

Two	16.5	19.6

Three	79.8	75.5

≥Four	0	0.8


Predictor Variables	B	β	sr2	t	p

R2 = .78***

Adjusted R2 = .77

Standard Error = 4.30


Security Level	NISTP192-SHA256	NISTP224-SHA256	NISTP224-SHA224	NISTP384-SHA256	NISTP384-SHA384

CB	Xn	i7	CB	Xn	i7	CB	Xn	i7	CB	Xn	i7	CB	Xn	i7

Sign & Encrypt with Certificate c	8.06	1.14	0.39	10.55	1.56	0.78	10.54	1.55	0.53	49.43	6.17	2.11	49.29	6.14	2.12


Region	Ergot limit in cereal grains for humans (ppm)	Ergot limit in animal feed (ppm)	Other comments

Australia and New Zealand	0.05	N/A	0–0.1% (T)

Canada	0–0.05	0.10–0.33	Varies with grade of wheat

European Union	0.05	0.10	–

Switzerland	0.02	N/A	0.05 limit on cereals destined for milling

Japan	0.04	N/A	–

United Kingdom	Zero tolerance	0.001	–

United States	0.3 (W, R)	0.3 (W, R)	0.1% (B, O, T)


	First story (Aladdin’s Lamp)	Second story (The Three Little Pigs)	Third story (Adopting a Star)

	Moral	No moral	Moral	No moral	Moral	No moral

TB	37	13	24	26	32	18

PC-NoIA	16	34	31	19	21	29

PC-IA	20	30	8	42	11	39

	χ2 = 19.51	χ2 = 22.82	χ2 = 18.04

	p < 0.001	p < 0.001	p < 0.001

	First story (Aladdin’s Lamp)	Second story (The Three Little Pigs)	Third story (Adopting a Star)

	Moral	No moral	Moral	No moral	Moral	No moral

PC-IA	20	30	8	42	11	39

	χ2 = 19.51	χ2 = 22.82	χ2 = 18.04

	p < 0.001	p < 0.001	p < 0.001


Participant Patients	Age	Gender	Lesion location	Hemi-paretic side	Etio-logy	Time since lesion (days)	ARAT (max = 57)	Max. grip force (kg) affected\non-affected	% max. grip force (%)	Moberg Pick-Up Test (s) affected\non-affected	Mono-filaments (g) affected\non-affected

1	76	F	Right precentral gyrus and right lenticular nucleus	left	H	36	57	12\16	75	16\12	0.4\0.4

2	49	M	Left parieto-occipital cortex, intra-ventricular and corpus callosum	right	H	120	57	42\39	100	25\13	0.4\0.07

3	25	M	Right temporo-parietal cortex	left	H	330	32	15/44	34	60\13	0.07\0.07

4	68	F	Left fronto-parietal cortex	right	I	19	57	11/15	73	19\14	0.07\0.4

5	46	M	Right sylvian and subdural hematoma	left	I	165	51	12/26	46	50\30	0.4\0.4

6	68	M	Left sylvian	right	I	315	40	18/37	49	60\22	0.07\0.4

7	40	M	Left thalamus	right	H	75	40	6/43	14	51\21	0.07\0.4

8	64	M	Left pons	right	I	40	57	38/30	100	32\24	0.4\0.4

9	50	F	Left precentral cortex and left semi-oval center	right	I	210	56	19/24	79	13\12	0.4\0.4

10	65	M	Left pons	right	I	180	57	17/39	43	26\17	0.4\0.4

Patients	55.1 (±15.7)	3 F/7M				149 (±112)	50.4 (±9.4)	31.3 (±10.7)	61.3 (±28.5)	35.2 (±18.3)	0.33 (±0.14)

Mean (±SD)								\19.0 (±11.7)		\17.8 (±6.2)	\0.27 (±0.18)

Controls Mean (±SD)	52.9 (±17.4)	4 F/6 M						35.1 (±11.4)		14.3 (±1.9)	0.14 (±0.14)

Participant Patients	Age	Gender	Lesion location	Hemi-paretic side	Etio-logy

1	76	F	Right precentral gyrus and right lenticular nucleus	left	H

2	49	M	Left parieto-occipital cortex, intra-ventricular and corpus callosum	right	H

3	25	M	Right temporo-parietal cortex	left	H

4	68	F	Left fronto-parietal cortex	right	I

5	46	M	Right sylvian and subdural hematoma	left	I

6	68	M	Left sylvian	right	I

7	40	M	Left thalamus	right	H

8	64	M	Left pons	right	I

9	50	F	Left precentral cortex and left semi-oval center	right	I

10	65	M	Left pons	right	I

Patients	55.1 (±15.7)	3 F/7M

Mean (±SD)

Controls Mean (±SD)	52.9 (±17.4)	4 F/6 M


Treatment (n = 5)	Dose (mg/kg)	Onset of sleep (min)	Duration of sleep (min)

Control	–	32.80 ± 7.03	128.20 ± 19.79

Hibiscus tiliaceus leaves	500	16.40 ± 1.03*	133.40 ± 13.87*

Hibiscus tiliaceus barks	500	13.80 ± 2.08*	101.40 ± 12.54*

Treatment (n = 5)

Control

Hibiscus tiliaceus leaves

Hibiscus tiliaceus barks


Category	Survey question

Awareness items	Do you know what colorectal cancer is?

	Do you know what a colon polyp is?

	Do you know what a cancer screening test is?

	Do you know the different types of screening tests available for colorectal cancer?

	Do you know what the following tests are:

	Fecal Occult Blood Test (FOBT)/ Stool Blood Test?

	Colonoscopy?

	Sigmoidoscopy?

	Do you know where you can obtain screening tests for colorectal cancer?

Knowledge items	Do you think a diet low in fat and high in fiber helps decrease the risk for developing colorectal cancer?

	Do you think physical activity decreases the risk of developing colorectal cancer?

	Do you think the risks for developing colorectal cancer increases after the age of 50?

	Do you think most patients survive colorectal cancer if it is found early and removed?

	Do you think you ONLY need colorectal cancer screening if you are having any symptoms?

Behavioral intention to obtain colorectal cancer screening	Do you plan on talking to your doctor about cancer of the colon and rectum in the future?

	Do you plan on getting screened for cancer of the colon and rectum in the future?

Behavioral intentions to promote colorectal cancer education	How likely are you to talk about colorectal cancer with your:

	Parents

	Grandparents

	Relatives (aunts, uncles, cousins)

	Peers (friends, colleagues, etc.)

	Community members

	Individuals at risk (50+ years of age, family history, etc.)

Category	Survey question

ness items	 know what colorectal cancer is?

	Do you know what a colon polyp is?

	Do you know what a cancer screening test is?

	Do you know the different types of screening tests available for colorectal cancer?

	Do you know what the following tests are:

	Fecal Occult Blood Test (FOBT)/ Stool Blood Test?

	Colonoscopy?

	Sigmoidoscopy?

	Do you know where you can obtain screening tests for colorectal cancer?

Knowledge items	Do you think a diet low in fat and high in fiber helps decrease the risk for developing colorectal cancer?

	Do you think physical activity decreases the risk of developing colorectal cancer?

	Do you think the risks for developing colorectal cancer increases after the age of 50?

	Do you think most patients survive colorectal cancer if it is found early and removed?

	Do you think you ONLY need colorectal cancer screening if you are having any symptoms?

Behavioral intention to obtain colorectal cancer screening	Do you plan on talking to your doctor about cancer of the colon and rectum in the future?

	Do you plan on getting screened for cancer of the colon and rectum in the future?

Behavioral intentions to promote colorectal cancer education	How likely are you to talk about colorectal cancer with your:

	Parents

	Grandparents

	Relatives (aunts, uncles, cousins)

	Peers (friends, colleagues, etc.)

	Community members

	Individuals at risk (50+ years of age, family history, etc.)


Characteristics	Preoperative with plasmapheresis group (PPG) N (33)	Preoperative without plasmapheresis group (NPPG) N (53)	P value

Male, n (%)	8 (24.2)	17 (32.1)	0.475

Age (years), (mean ± SD)	44.2 ± 11.6	44.0 ± 15.3	0.933

Underlying disease (DM or HT or dyslipidemia)	17 (51.5)	30 (56.6)	0.663

Osserman classification	 	 	0.611

 I	2 (6.1)	5 (9.4)	0.703

 IIA	6 (18.2)	14 (26.4)	0.440

 IIB	21 (63.6)	31 (58.5)	0.658

 III	4 (12.1)	3 (5.7)	0.421

History of myasthenic crisis at any time 	16 (48.5)	12 (22.6)	0.018

History of myasthenic crisis within one month before surgery	7 (21.2)	1 (1.9)	0.005

History of plasmapheresis within one month before surgery	11 (33.3)	5 (9.4)	0.009

Ocular involvement	15 (45.5)	25 (47.2)	1.000

Neck muscle motor power (mean ± SD)	4.5 ± 0.7 	4.8 ± 0.4	0.025

Upper extremities motor power (mean ± SD)	4.4 ± 0.7	4.7 ± 0.5	0.009

lower extremities motor power (mean ± SD)	4.3 ± 0.8	4.7 ± 0.5	0.004

Respiratory involvement	6 (18.2)	1 (1.9)	0.012

Bulbar involvement	13 (39.4)	6 (11.3)	0.003

Mestinon use 	33 (100)	47 (88.7)	0.078

Dose of mestinon (mg/day) (mean ± SD)	238.2 ± 132.0	204.9 ± 88.1	0.179

Prednisolone use 	30 (91.0)	48 (91.0)	1.000

 Dose of prednisolone (mg/day) (mean ± SD)	36.0 ± 19.8	29.3 ± 14.9	0.094

Azathioprine use	16 (48.5)	21 (39.6)	0.503

Dose of Azathioprine (mg/day) (mean ± SD)	65.6 ± 22.1	73.8 ± 28.0	0.342

FVC (mean ± SD)	1503.3 ± 304.7	2552.9 ± 221.5	0.019

Probability of receiving treatment (propensity score)*	0.53 ± 0.32	0.26 ± 0.15	<0.001


Gene symbol	Gene name & function	Fold change	p-value

ompC	Outer membrane protein C porin - permeability	0.97	NS

ompF	Outer membrane protein F porin - permeability	0.14	< .001

micF	Anti-sense RNA - negative regulation of OmpF translation	2.27	< .001

marA	Multiple antibiotic resistance (mar) protein A - transcription activator of mar regulon	2.01	< .001

marB	mar protein B	2.22	< .001

marR	mar operon repressor	1.80	.003

soxS	Regulatory protein SoxS - superoxide response regulon	0.37	< .001

acrA	Acriflavine resistance protein A - antibiotic and bile resistance	1.89	< .001

acrB	Acriflavine resistance protein B - antibiotic and bile resistance	2.21	< .001

acrR	Acriflavine resistance protein R –transcription regulator	2.83	< .001

yceE	Multidrug resistance protein - antibiotic and bile resistance	2.04	.002

yojI	Drug (microcin) efflux pump	2.49	< .001

Gene symbol	Gene name & function	Fold change	p-value

marA	Multiple antibiotic resistance (mar) protein A - transcription activator of mar regulon	2.01	< .001

marB	mar protein B	2.22	< .001

marR	mar operon repressor	1.80	.003

soxS	Regulatory protein SoxS - superoxide response regulon	0.37	< .001

acrA	Acriflavine resistance protein A - antibiotic and bile resistance	1.89	< .001

acrB	Acriflavine resistance protein B - antibiotic and bile resistance	2.21	< .001

acrR	Acriflavine resistance protein R –transcription regulator	2.83	< .001

yceE	Multidrug resistance protein - antibiotic and bile resistance	2.04	.002

yojI	Drug (microcin) efflux pump	2.49	< .001


Multiplex PCR assay	Biochemical test	TOTAL

Nitrate positive	Nitrate negative

Nitrate positive	133	5	138

Nitrate negative	5	205	210

Total	138	210	348


Categories	Search terms

Participants	(child OR children OR adolescent* OR pediatric*OR paediatric*) AND

Disease	(sleeplessness OR ‘chronic insomnia’ ORinsomniac OR insomnia OR insomni* OR ‘sleep initiation andmaintenance disorders’) AND

Interventions	(CBT OR ‘cognitive behavioural therapy’ OR‘cognitive behavioral therapy’ OR ‘cognitive behaviortherapy’ OR ‘cognitive behavioural therapies’ OR ‘cognitivebehavioral therapies’ OR ‘cognitive behavior therapies’ OR‘cognitive analytic therapy’ OR ‘sleep hygiene’ OR ‘stimuluscontrol’ OR ‘relaxation’ OR ‘relaxation therapy’ OR‘relaxation techniques’ OR ‘behavior modification’ OR‘behavior therapy’ OR ‘cognitive therapy’ OR ‘imagery’ OR‘biofeedback’ OR ‘counseling’ OR ‘family therapy’ OR‘psychoanalytic therapy’ OR ‘psychotherapy’)

Categories	Search terms

Interventions	(CBT OR ‘cognitive behavioural therapy’ OR‘cognitive behavioral therapy’ OR ‘cognitive behaviortherapy’ OR ‘cognitive behavioural therapies’ OR ‘cognitivebehavioral therapies’ OR ‘cognitive behavior therapies’ OR‘cognitive analytic therapy’ OR ‘sleep hygiene’ OR ‘stimuluscontrol’ OR ‘relaxation’ OR ‘relaxation therapy’ OR‘relaxation techniques’ OR ‘behavior modification’ OR‘behavior therapy’ OR ‘cognitive therapy’ OR ‘imagery’ OR‘biofeedback’ OR ‘counseling’ OR ‘family therapy’ OR‘psychoanalytic therapy’ OR ‘psychotherapy’)


Primer name	Sequence	Used to generate data for figure:

IAP-F [8]	5′-ATAATCTGCGCATGAGCCAAGG-3′	1

IAP-R [8]	5′-AGGAAGAACACCACAGACCAGA-3′	1

Tagln F	5′-GCATAAGAGGGAGTTCACAGACA-3′	3, 4, S11

Tagln R	5′-GCCTTCCCTTTCTAACTGATGATC-3′	3, 4, S11

Myh11 F	5′-CAGTTGGACACTATGTCAGGGAAA-3′	3, 4, S11

Myh11 R	5′-ATGGAGACAAATGCTAATCAGCC-3′	3, 4, S11

1F [33]	5′-GCGCCAGTCATCCGATAGACT-3′	S2

K1R [33]	5′-AAGGCTTTATTGGGAACACG-3′	S2

MoA 5 bbone	5′-GCGCCAGTCCTCCGATTGAC-3′	S13

XMRV adapt MoA	5′ -TGAGAACGCTGGACTTTCCATC	S13

5bbone R	GATGTTAGGCCATTAAGGAG-3′

XMRV adapt MoA	5′-AACTCCTCCGGCCGGAACAGC	S13

env F	ATGAGACAGCGGACCCGGACT-3′

MoA adapt XMRV	5′-GAAACTGAATAAAATCTTTTAT	S13

env R	GGCTCGTACTCTATAGGCTT-3′

MoA adapt XMRV	5′-GAAGAAGTGGAATCACGTGA	S13

3bbone F	ATAGATAAAATAAAAGATTTTA-3′

MoA 3bbone R	5′-TGCAACTGCAAG	S13

AGGGTTTATTGG-3′

XMRV 5bbone F	5′-GCGCCAGTCCTCCGATTGAC-3′	S14

MoA adapt XMRV	5′-CTCCTTAATGGCCTAACATCG	S14

env F	ATGGAAAGTCCAGCGTTCTCA-3′

MoA adapt XMRV	5′-GAAACTGAATAAAATCTTTTA	S14

env R	TGGCTCGTACTCTATAGGCTT-3′

XMRV adapt MoA	5′-TAAAATCTTTTATTTTATCTA	S14

env R	TTCACGTGATTCCACTTCTTC-3′

XMRV 3bbone F	5′-AAGCCTATAGAGTACGAGCCA	S14

TAAAAGATTTTATTCAGTTTC-3′

XMRV 3bbone R	5′-TTGCAAACAGCAAAAGGCTTT-3′	S14

XPR1 F [35]	5′- TAATTCAGAAGAATCAGGAATT-3′	S16

XPR1 R [35]	5′-CGAGTGACCTCGTTCTTTG-3′	S16

Primer name	Sequence

IAP-F [8]	5′-ATAATCTGCGCATGAGCCAAGG-3′

IAP-R [8]	5′-AGGAAGAACACCACAGACCAGA-3′

Tagln F	5′-GCATAAGAGGGAGTTCACAGACA-3′

Tagln R	5′-GCCTTCCCTTTCTAACTGATGATC-3′

Myh11 F	5′-CAGTTGGACACTATGTCAGGGAAA-3′

Myh11 R	5′-ATGGAGACAAATGCTAATCAGCC-3′

1F [33]	5′-GCGCCAGTCATCCGATAGACT-3′

K1R [33]	5′-AAGGCTTTATTGGGAACACG-3′

MoA 5 bbone	5′-GCGCCAGTCCTCCGATTGAC-3′

XMRV adapt MoA	5′ -TGAGAACGCTGGACTTTCCATC

5bbone R	GATGTTAGGCCATTAAGGAG-3′

XMRV adapt MoA	5′-AACTCCTCCGGCCGGAACAGC

env F	ATGAGACAGCGGACCCGGACT-3′

MoA adapt XMRV	5′-GAAACTGAATAAAATCTTTTAT

env R	GGCTCGTACTCTATAGGCTT-3′

MoA adapt XMRV	5′-GAAGAAGTGGAATCACGTGA

3bbone F	ATAGATAAAATAAAAGATTTTA-3′

MoA 3bbone R	5′-TGCAACTGCAAG

AGGGTTTATTGG-3′

XMRV 5bbone F	5′-GCGCCAGTCCTCCGATTGAC-3′

MoA adapt XMRV	5′-CTCCTTAATGGCCTAACATCG

env F	ATGGAAAGTCCAGCGTTCTCA-3′

MoA adapt XMRV	5′-GAAACTGAATAAAATCTTTTA

env R	TGGCTCGTACTCTATAGGCTT-3′

XMRV adapt MoA	5′-TAAAATCTTTTATTTTATCTA

env R	TTCACGTGATTCCACTTCTTC-3′

XMRV 3bbone F	5′-AAGCCTATAGAGTACGAGCCA

TAAAAGATTTTATTCAGTTTC-3′

XMRV 3bbone R	5′-TTGCAAACAGCAAAAGGCTTT-3′

XPR1 F [35]	5′- TAATTCAGAAGAATCAGGAATT-3′

XPR1 R [35]	5′-CGAGTGACCTCGTTCTTTG-3′


Health Unit	Health Region Peer Groupa	Land area (km2)	Population density (persons/km2)(Census, 2011)	Populationage 65+ (% of total)(Census, 2011)	Visible minorities (% of population)(NHS, 2011)

North Bay Parry Sound District	Sparsely populated urban-rural mix	16,801	7.4	19%	1.7%

Simcoe Muskoka District	Moderately populated urban centres	8736	58	16%	4%

York Region	Highly populated urban centres	1762	586.0	12%	43%

Health Unit	Health Region Peer Groupa	Land area (km2)	Population density (persons/km2)(Census, 2011)	Populationage 65+ (% of total)(Census, 2011)

North Bay Parry Sound District	Sparsely populated urban-rural mix	16,801	7.4	19%

Simcoe Muskoka District	Moderately populated urban centres	8736	58	16%

York Region	Highly populated urban centres	1762	586.0	12%

Visible minorities (% of population)(NHS, 2011)

1.7%

4%

43%


Initial pH	pH range	ΔpH

5.1	5.1–3.7	1.4

	6.0 –3.	2.


 	KNH (%)	AKUH (%)

Attitude statements	SA	A	U	D	SD	SA	A	U	D	SD

A computer increases costs by increasing the nurses workload	5.2	11	4.5	35.5	43.9	16.3	Nil	2.3	23.3	55.8

Costs of health care are likely to increase because of computers	8.4	18.8	4.6	34.4	33.8	18.2	4.6	29.6	34.1	2.3

The time spent using a computer is out of proportion to the benefits	5.9	9.2	9.9	32.2	42.8	7.3	2.4	36.6	41.5	13.6

Computers represent a violation of patient privacy	6.7	17.3	8	31.3	36.7	17.1	14.6	22	34.2	12.2

Only one person at a time can use a computer terminal and, therefore, staff efficiency is inhibited.	16.2	27.9	10.4	26.6	18.2	27.3	9.1	15.9	20.5	12.2

Computerization of nursing data offers nurses a remarkable opportunity to improve patient care	49.7	35.5	2.6	5.2	6.5	40.9	29.6	22.7	6.8	27.3

Computers contain too much personal data to be used in an area as open as a nursing station	14.7	27.6	5.1	30.1	22.4	11.6	20.9	4.7	44.2	18.6

Computers can cause nurses to give less time to quality nursing care	8.3	11.5	6.4	35.3	38.5	14	14	4.7	14	53.5

If I had my way, nurses would never have to use computers	4	4.6	4	15.1	72.4	4.7	4.7	2.3	16.3	72.1

Computers should only be used in the financial department	4.6	0.7	2.6	17.7	73.9	4.9	2.4	2.4	9.8	80.5

Computers make nurses jobs easier	51.7	31.1	6	7.3	4	60.5	25.6	7	4.7	2.3

Paperwork for nurses can be reduced greatly by the use of computers	69.9	20.9	5.2	1.3	2.6	56.8	29.6	2.3	9.1	2.3

Orientation for new employees takes longer because of computers	7.1	8.4	11.7	38.3	34.4	4.7	11.6	9.3	37.2	37.2

Nursing data cannot be manipulated using computers	13.6	23.9	9.7	27.1	25.8	12.2	26.8	4.9	36.6	19.5

Computers save steps and allow the nursing staff to become more efficient	43.5	35.7	6.5	10.4	3.9	47.7	29.6	2.3	13.6	6.8

The more computers in an institution, the less number of jobs for employees	21.8	25	10.9	24.4	18	29.6	22.7	6.8	20.5	20.5

Increased computer use will allow nurses more time to give patient care	45.3	26	9.3	14	5.3	37.8	29.7	8.1	16.2	8.1

Because of computers, nurses will face more law suits	9.5	15.5	12.2	29.1	33.8	3	15.2	9.1	36.4	36.4

Computers can cause a decrease in communication between hospital departments	7.3	11.3	6.7	28.7	46	16.7	16.7	Nil	30.6	36.1

Confidentiality will be sacrificed by patient records being computerized	14	17.3	6	33.3	29.3	32.4	27	2.7	18.9	18.9

	KNH (%)

Attitude statements	SA	A	U	D	SD

A computer increases costs by increasing the nurses workload	5.2	11	4.5	35.5	43.9

Costs of health care are likely to increase because of computers	8.4	18.8	4.6	34.4	33.8

The time spent using a computer is out of proportion to the benefits	5.9	9.2	9.9	32.2	42.8

Computers represent a violation of patient privacy	6.7	17.3	8	31.3	36.7

Only one person at a time can use a computer terminal and, therefore, staff efficiency is inhibited.	16.2	27.9	10.4	26.6	18.2

Computerization of nursing data offers nurses a remarkable opportunity to improve patient care	49.7	35.5	2.6	5.2	6.5

Computers contain too much personal data to be used in an area as open as a nursing station	14.7	27.6	5.1	30.1	22.4

Computers can cause nurses to give less time to quality nursing care	8.3	11.5	6.4	35.3	38.5

If I had my way, nurses would never have to use computers	4	4.6	4	15.1	72.4

Computers should only be used in the financial department	4.6	0.7	2.6	17.7	73.9

Computers make nurses jobs easier	51.7	31.1	6	7.3	4

Paperwork for nurses can be reduced greatly by the use of computers	69.9	20.9	5.2	1.3	2.6

Orientation for new employees takes longer because of computers	7.1	8.4	11.7	38.3	34.4

Nursing data cannot be manipulated using computers	13.6	23.9	9.7	27.1	25.8

Computers save steps and allow the nursing staff to become more efficient	43.5	35.7	6.5	10.4	3.9

The more computers in an institution, the less number of jobs for employees	21.8	25	10.9	24.4	18

Increased computer use will allow nurses more time to give patient care	45.3	26	9.3	14	5.3

Because of computers, nurses will face more law suits	9.5	15.5	12.2	29.1	33.8

Computers can cause a decrease in communication between hospital departments	7.3	11.3	6.7	28.7	46

Confidentiality will be sacrificed by patient records being computerized	14	17.3	6	33.3	29.3


Epitope	Start position	Combined score

FIEYCNHCY	64	2.4978

FRYEFTAPF	56	2.0697

RYEFTAPFI	57	1.6395

ESLLHQASW	19	1.2675

SFVTDLEKY	44	1.1582

Epitope	Start position	Combined score

FRYEFTAPF	56	2.0697

RYEFTAPFI	57	1.6395

ESLLHQASW	19	1.2675

SFVTDLEKY	44	1.1582


Cellulase	Percentage of mass/area remove	Film swelling

RT	Topt

Cel9A	5	11	No

Cel9A-CBM	12	32	Yes

Cel5A	1	4	No

Cel5A-CBM	16	35	Yes

Cellulase	Percentage of mass/area remove

RT

Cel9A	5

Cel9A-CBM	12

Cel5A	1

Cel5A-CBM	16

Percentage of mass/area remove	Film swelling

Topt

11	No

32	Yes

4	No

35	Yes


OPINIONS ABOUT USE OF MORPHINE	GP AGREEMENT (%)	HP AGREEMENT (%)	% DIFFERENCE GP - HP	P-Value

It means that it is serious (GP n = 171; HP n = 399)	96 (56,1)	37 (9,3)	46,8	0,000*

There is a risk to develop dependency (GP n = 171; HP n = 405)	70 (41.0)	6 (1,5)	39,5	0,000*

There is a risk of delirium or euphoria (GP n = 171; HP n = 405)	68 (39.8)	18 (4,4)	35,4	0,000*

It does diminish the surviving period (GP n = 171; HP n = 407)	61 (35,7)	13 (3,2)	32,5	0,002*

There is a risk of somnolence or sedation (PG n = 170; PS n = 403)	74 (43,5)	123 (30,5)	13,0	0,000*

It can lead to increasing doses (GP n = 170; HP n = 403)	85 (50,0)	105 (26,1)	23,9	0,000*

It is a sign of limited life expectancy (GP n = 171 - HP n = 409)	47 (27,5)	4 (1,0)	26,5	0,000*

It increases legal risks in relation to other medication (GP n = 171; HP n = 407)	85 (49,7)	229 (56,3)	-6,6	0,149

There is a risk of discrimination (PG n = 169; PS n = 397)	33 (19,5)	10 (2,5)	17,0	0,000*

OPINIONS ABOUT USE OF MORPHINE	GP AGREEMENT (%)	HP AGREEMENT (%)	% DIFFERENCE GP - HP	P-Value

It means that it is serious (GP n = 171; HP n = 399)	96 (56,1)	37 (9,3)	46,8	0,000*

There is a risk to develop dependency (GP n = 171; HP n = 405)	70 (41.0)	6 (1,5)	39,5	0,000*

There is a risk of delirium or euphoria (GP n = 171; HP n = 405)	68 (39.8)	18 (4,4)	35,4	0,000*

It does diminish the surv	61	13	3	0,002

iving period (GP n = 171; HP n = 407)	 (35,7)	 (3,2)	2,5	*

There is a risk of somnolence or sedation (PG n = 170; PS n = 403)	74 (43,5)	123 (30,5)	13,0	0,000*

It can lead to increasing doses (GP n = 170; HP n = 403)	85 (50,0)	105 (26,1)	23,9	0,000*

It is a sign of limited life expectancy (GP n = 171 - HP n = 409)	47 (27,5)	4 (1,0)	26,5	0,000*

It increases legal risks in relation to other medication (GP n = 171; HP n = 407)	85 (49,7)	229 (56,3)	-6,6	0,149

There is a risk of discrimination (PG n = 169; PS n = 397)	33 (19,5)	10 (2,5)	17,0	0,000*


	Genotypes

	GG

N = 141	32

New coronary lesion (mean)	0.34 ± 0.48

Subjects with new coronary lesions (%)	11 (34.3)

New coronary occlusions (mean)	0.03 ± 0.18

Subjects with new coronary occlusions (%)	1 (3.1)

Average final MLD (mm)	1.54 ± 0.40

Change in MLD (mm)	-0.09 ± 0.25


	Website (n = 24)	JawboneTM/UP app (n = 23)	F2F (group) (n = 19)	F2F (1-2-1) (n = 22)	Facebook group (n = 24)	Food & nutrient report (n = 24)	GymstickTM (n = 23)	TEMPlateTM dinner disc (n = 16)

Provided me with useful information about healthy eating	4.0 ± 0.6	3.2 ± 1.0	4.1 ± 0.6	4.5 ± 0.7	3.8 ± 0.8	4.4 ± 0.9	NA	3.9 ± 0.9

Provided me with useful information about exercise	4.2 ± 0.6	3.9 ± 0.9	4.2 ± 0.9	4.2 ± 0.8	3.7 ± 0.8	NA	NA	NA

Provided me with useful information about stress	3.7 ± 0.7	3.0 ± 0.9	3.6 ± 0.8	4.0 ± 0.9	3.5 ± 0.8	NA	NA	NA

Helped me to attain my goals	3.6 ± 0.8	3.8 ± 0.9	3.9 ± 1.0	4.0 ± 0.9	3.7 ± 0.9	4.1 ± 1.0	3.7 ± 1.0	3.3 ± 0.9

Motivated me	3.5 ± 0.9	4.1 ± 0.7	4.3 ± 0.7	4.0 ± 0.8	3.6 ± 0.8	4.0 ± 0.9	3.5 ± 1.0	3.3 ± 1.1

Made me feel accountable	3.3 ± 0.9	4.0 ± 1.0	3.8 ± 0.9	4.1 ± 0.8	3.5 ± 1.0	4.2 ± 0.9	3.6 ± 1.0	3.2 ± 0.9

Was easy to use/navigate	4.3 ± 0.6	4.0 ± 0.9	NA	NA	4.2 ± 0.8	NA	3.8 ± 1.0	3.5 ± 1.2

Content was easy to understand	4.3 ± 0.4	4.1 ± 0.7	4.4 ± 0.6	4.4 ± 0.6	4.2 ± 0.8	4.1 ± 0.9	NA	NA

Was visually appealing	4.0 ± 0.7	4.0 ± 0.9	NA	NA	3.8 ± 0.8	3.9 ± 0.9	NA	3.4 ± 0.9

Was supportive in answering any queries/questions	NA	NA	4.5 ± 0.7	4.5 ± 0.6	3.7 ± 0.8	NA	NA	NA

Satisfaction	4.0 ± 0.6	4.2 ± 1.1	4.1 ± 0.8	4.3 ± 0.8	Not asked	4.2 ± 0.8	4.0 ± 0.9	3.0 ± 0.9


Database		Search strategy

Embase	#1	‘headache*’:ti,ab OR ‘cephalgia*’:ti,ab OR ‘cephalalgia*’:ti,ab OR ‘cranialgia*’:ti,ab OR ‘head ache*’:ti,ab OR ‘cephalodynia*’:ti,ab OR ‘cephalea*’:ti,ab OR ‘cerebral pain’:ti,ab OR ‘head pain’:ti,ab OR ‘eye pain’:ti,ab

#2	‘neuroimaging’:ti,ab OR ‘brain imaging’:ti,ab OR ‘tomography’:ti,ab OR ‘mri’:ti,ab OR ‘magnetic resonance imaging’:ti,ab OR ‘mr imaging’:ti,ab OR ‘nmr imaging’:ti,ab

#3	#1AND #2

Restrict to humans	#4	#3 AND ‘human’/de

Filter by type of study	#5	#4 AND (‘clinical study’/de OR ‘clinical trial’/de OR ‘cohort analysis’/de OR ‘comparative study’/de OR ‘controlled clinical trial’/de OR ‘controlled study’/de OR ‘family study’/de OR ‘major clinical study’/de OR ‘medical record review’/de OR ‘observational study’/de OR ‘prospective study’/de OR ‘randomized controlled trial’/de OR ‘retrospective study’/de OR ‘systematic review’/de)

Database

Embase	#1

#2

#3

Restrict to humans	#4

Filter by type of study	#5

Search strategy

‘headache*’:ti,ab OR ‘cephalgia*’:ti,ab OR ‘cephalalgia*’:ti,ab OR ‘cranialgia*’:ti,ab OR ‘head ache*’:ti,ab OR ‘cephalodynia*’:ti,ab OR ‘cephalea*’:ti,ab OR ‘cerebral pain’:ti,ab OR ‘head pain’:ti,ab OR ‘eye pain’:ti,ab

‘neuroimaging’:ti,ab OR ‘brain imaging’:ti,ab OR ‘tomography’:ti,ab OR ‘mri’:ti,ab OR ‘magnetic resonance imaging’:ti,ab OR ‘mr imaging’:ti,ab OR ‘nmr imaging’:ti,ab

#1AND #2

#3 AND ‘human’/de

#4 AND (‘clinical study’/de OR ‘clinical trial’/de OR ‘cohort analysis’/de OR ‘comparative study’/de OR ‘controlled clinical trial’/de OR ‘controlled study’/de OR ‘family study’/de OR ‘major clinical study’/de OR ‘medical record review’/de OR ‘observational study’/de OR ‘prospective study’/de OR ‘randomized controlled trial’/de OR ‘retrospective study’/de OR ‘systematic review’/de)


Antibiotic name	MSO(central government	MCD	CG1	CG2	CPA(Delhi state government)

Azithromycin cap/tab	No rate available	6.31	No rate available	9.45	No rate available

Ceftriaxone injection	14.99	18.28	16.46	15.50	8.50

Erythromycin Stearate	1.43	1.32	2.04	1.68	0.85

cap/tab

Gentamicin eye drops	No rate available	0.61	0.81	1.21	0.58

Gentamicin injection	No rate available	1.40	1.53	2.49	1.52

Roxithromycin cap/tab	1.04	1.29	No rate available	No rate available	0.74

Antibiotic name	MSO(central government	MCD	CG1	CG2	CPA(Delhi state government)

Gentamicin injection	No rate available	1.40	1.53	2.49	1.52

Roxithromycin cap/tab	1.04	1.29	No rate available	No rate available	0.74


miRNA Migr. / Inv. / Met.	Targets	Cells / Tissue	Expression	Function	Reference

miR-17 family (20a, 20b)	TGFßR2	A549/CDDP	down	TGFßR2 suppressor, reverses CDDP-resistance and suppresses metastases	[81]

miR-21	PTEN	Serum, NSCLC cells	up	Promotes migration, invasion and metastasis	[9]

mir-26b	PTEN	NSCLC tissue, NSCLC cells	down	Regulates NSCLC migration and CDDP-chemosensitivity	[78]

miR-27a	RKIP	A549/CDDP	up	Regulates EM-transition and CDDP-resistance	[82]

miR-98	PAK1	NSCLC tissue, A549/PAR	down	Inversely regulates PAK1, inhibits migration and invasion	[51]

miR-182	PDCD4	A549 cells	up	Induces resistance to CDDP by targeting PDCD4	[84]

miR-200c	n. d.	NSCLC cell lines (n=9)	down	Inversely correlates with aggressive, invasive and chemoresistant phenotype	[8]

miR-206	MET	NSCLC tissue, A549/CDDP, H1299/CDDP	down	Inhibits CDDP-resistance via MET dependent PI3K/AKT/mTOR pathways	[80]

miR-217	KRAS	NSCLC tissue, A549/PAR	down	Inhibits proliferation, migration and invasion, promotes apoptosis and sensitivity to CDDP	[79]

DNA damage response

miR-17/miR-92 families	TGFßR2, CDKN1A, RAD21	A549/CDDP	down	Influence CDDP-resistance by synergistic and combined regulation of their target genes	[127]

miR-33b-3p	P21WAF1	A549/CDDP	up	Impairs the DNA damage response	[128]

miR-92

miR-138	ERCC1	A549/CDDP	up	Negatively regulates ERCC1 expression	[38]

miR-155	APAF-1	NSCLC tissue, A549/PAR	up	Inhibits sensitivity to CDDP via negative regulation of Apaf-1	[37]

miR-509-3-5p	PLK1	CDDP-treated A549/PAR	down	Tumor suppressor, causes aberrant mitosis and anti-proliferative effects by suppressing PLK1	[20]

miR-630	ATM, H2AX, p53	A549/PAR CDDP-treated	up	Blocks DNA-damage response	[13]

Drug uptake

miR-15b	PEBP4	A549/CDDP, NSCLC tissue	up	Suppresses PEBP4 expression and contribute to CDDP-resistance	[129]

miR-31-p	Dicer	A549 cells	n. d.	Enhances sensitivity to CDDP by repressing Dicer	[130]

miR-34a	PEBP4, MYCN	A549/PAR	up	Modulates CDDP-sensitivity in NSCLC cells by regulating PEBP4 expression	[131]

miR-106a	ABCA1	A549/CDDP	up	Induces CDDP-resistance by targeting ABCA1 and inhibiting apoptosis	[68]

miR-148b	DNMT1	A549/CDDP, SPC-A1/CDDP	down	Influence CDDP-sensitivity, cell viability and apoptosis	[57]

miR-181a	PTEN	A549/CDDP	up	Regulates epithelial-mesenchymal transition and metastatic properties of NSCLC cells	[46]

miR-185-5p	ABCC1	A549/CDDP	down	Promotes CDDP-induced apoptosis by suppressing ABCC1	[69]

miR-495	ATP7A	NSCLC tissue, A549/CDDP	down	Negatively regulates ATP7A and modulates CDDP-induced apoptosis	[70]

miR-503	FANCA	NSCLC tissue, A549/CDDP	down	Regulates CDDP-resistance by targeting FANCA	[102]

miRNA Migr. / Inv. / Met.	Targets	Cells / Tissue

miR-17 family (20a, 20b)	TGFßR2	A549/CDDP

miR-21	PTEN	Serum, NSCLC cells

mir-26b	PTEN	NSCLC tissue, NSCLC cells

miR-27a	RKIP	A549/CDDP

miR-98	PAK1	NSCLC tissue, A549/PAR

miR-182	PDCD4	A549 cells

miR-200c	n. d.	NSCLC cell lines (n=9)

miR-206	MET	NSCLC tissue, A549/CDDP, H1299/CDDP

miR-217	KRAS	NSCLC tissue, A549/PAR

DNA damage response

miR-17/miR-92 families	TGFßR2, CDKN1A, RAD21	A549/CDDP

miR-33b-3p	P21WAF1	A549/CDDP

miR-92

miR-138	ERCC1	A549/CDDP

miR-155	APAF-1	NSCLC tissue, A549/PAR

miR-509-3-5p	PLK1	CDDP-treated A549/PAR

miR-630	ATM, H2AX, p53	A549/PAR CDDP-treated

Drug uptake

miR-15b	PEBP4	A549/CDDP, NSCLC tissue

miR-31-p	Dicer	A549 cells

miR-34a	PEBP4, MYCN	A549/PAR

miR-106a	ABCA1	A549/CDDP

miR-148b	DNMT1	A549/CDDP, SPC-A1/CDDP

miR-181a	PTEN	A549/CDDP

miR-185-5p	ABCC1	A549/CDDP

miR-495	ATP7A	NSCLC tissue, A549/CDDP

miR-503	FANCA	NSCLC tissue, A549/CDDP

Expression	Function	Reference

down	TGFßR2 suppressor, reverses CDDP-resistance and suppresses metastases	[81]

up	Promotes migration, invasion and metastasis	[9]

down	Regulates NSCLC migration and CDDP-chemosensitivity	[78]

up	Regulates EM-transition and CDDP-resistance	[82]

down	Inversely regulates PAK1, inhibits migration and invasion	[51]

up	Induces resistance to CDDP by targeting PDCD4	[84]

down	Inversely correlates with aggressive, invasive and chemoresistant phenotype	[8]

down	Inhibits CDDP-resistance via MET dependent PI3K/AKT/mTOR pathways	[80]

down	Inhibits proliferation, migration and invasion, promotes apoptosis and sensitivity to CDDP	[79]

DNA damage response

down	Influence CDDP-resistance by synergistic and combined regulation of their target genes	[127]

up	Impairs the DNA damage response	[128]

miR-92

up	Negatively regulates ERCC1 expression	[38]

up	Inhibits sensitivity to CDDP via negative regulation of Apaf-1	[37]

down	Tumor suppressor, causes aberrant mitosis and anti-proliferative effects by suppressing PLK1	[20]

up	Blocks DNA-damage response	[13]

Drug uptake

up	Suppresses PEBP4 expression and contribute to CDDP-resistance	[129]

n. d.	Enhances sensitivity to CDDP by repressing Dicer	[130]

up	Modulates CDDP-sensitivity in NSCLC cells by regulating PEBP4 expression	[131]

up	Induces CDDP-resistance by targeting ABCA1 and inhibiting apoptosis	[68]

down	Influence CDDP-sensitivity, cell viability and apoptosis	[57]

up	Regulates epithelial-mesenchymal transition and metastatic properties of NSCLC cells	[46]

down	Promotes CDDP-induced apoptosis by suppressing ABCC1	[69]

down	Negatively regulates ATP7A and modulates CDDP-induced apoptosis	[70]

down	Regulates CDDP-resistance by targeting FANCA	[102]


Gene ID	Log2 (RPKMOXR/RPKMWT)	Description

0 h	6 h	24 h

Catalase (CAT)

Os06t0727200-01	0.79	1.36 **	0.79	catalase isozyme B (EC 1.11.1.6)

Ascorbate peroxidase (APX)

Os04t0602100-01	−1.77 *	−2.21 *	−1.34 *	l-ascorbate peroxidase

Peroxiredoxin (PrxR)

Os06t0196300-01	−1.64 *	−0.49	0.77	similar to peroxiredoxin Q

Glutathione S-transferase (GST)

Os04t0435500-01	−0.72	−1.03 *	−0.15	glutathione S-transferase, c-terminal-like domain containing protein

Os10t0530500-01	−1.42 *	−1.78 *	−2.0 *	similar to glutathione-S-transferase

Peroxidase superfamily protein

Os07t0677200-01	−0.04	2.81 **	0.64	peroxidase

Os07t0677400-00	−1.47 *	−0.28	−0.02	peroxidase.

Os04t0688100-01	0.45	2.21 **	0.18	peroxidase (EC 1.11.1.7)

Os04t0688100-02	0.79	1.87 **	0.58	peroxidase (EC 1.11.1.7)

Os04t0688500-01	0.9	2.72 **	1.21 **	peroxidase (EC 1.11.1.7)

Os10t0109300-01	0.35	1.94 **	0.17	similar to peroxidase (EC 1.11.1.7)

Os01t0263300-01	0.44	1.42 **	−0.6	similar to peroxidase 72 precursor (EC 1.11.1.7)

Os01t0962700-01	0.47	1.11 **	−0.16	similar to peroxidase 12 precursor (EC 1.11.1.7)

Os01t0963000-01	1.01 **	4.55 **	1.38 **	similar to peroxidase BP 1 precursor

Os06t0547400-01	0.73	1.76 **	1.03 **	similar to peroxidase P7 (EC 1.11.1.7)

Os06t0695500-01	0.01	2.19 **	−0.44	similar to peroxidase 16 precursor (EC 1.11.1.7)

Os04t0688300-01	1.02 **	3.24 **	1.77 **	Haem peroxidase, plant/fungal/bacterial family protein.

Os01t0326300-01	−0.07	1.92**	0.24	Haem peroxidase, plant/fungal/bacterial family protein.

Os06t0521500-01	1.26 **	3.09 **	0.82	Haem peroxidase family protein.

Os06t0306300-01	0.42	1.94 **	0	Haem peroxidase domain containing protein.

Os02t0684400-01	0.24	1.33 **	0	similar to OXS3 (OXIDATIVE STRESS 3)

Dehydrogenase/reductase

Os04t0531900-01	0.62	1.05 **	−0.07	short-chain dehydrogenase/reductase SDR domain-containing protein

Os11t0484500-01	0.31	−0.76	−1.23 *	similar to 6-phosphogluconate dehydrogenase

Gene ID	Log2 (RPKMOXR/RPKMWT)	Description

0 h	6 h	24 h

Os01t0263300-01	0.44	1.42 **	−0.6	similar to peroxidase 72 precursor (EC 1.11.1.7)

Os01t0962700-01	0.47	1.11 **	−0.16	similar to peroxidase 12 precursor (EC 1.11.1.7)

Os01t0963000-01	1.01 **	4.55 **	1.38 **	similar to peroxidase BP 1 precursor

Os06t0547400-01	0.73	1.76 **	1.03 **	similar to peroxidase P7 (EC 1.11.1.7)

Os06t0695500-01	0.01	2.19 **	−0.44	similar to peroxidase 16 precursor (EC 1.11.1.7)

Os04t0688300-01	1.02 **	3.24 **	1.77 **	Haem peroxidase, plant/fungal/bacterial family protein.

Os01t0326300-01	−0.07	1.92**	0.24	Haem peroxidase, plant/fungal/bacterial family protein.

Os06t0521500-01	1.26 **	3.09 **	0.82	Haem peroxidase family protein.

Os06t0306300-01	0.42	1.94 **	0	Haem peroxidase domain containing protein.

Os02t0684400-01	0.24	1.33 **	0	similar to OXS3 (OXIDATIVE STRESS 3)

Dehydrogenase/reductase

Os04t0531900-01	0.62	1.05 **	−0.07	short-chain dehydrogenase/reductase SDR domain-containing protein

Os11t0484500-01	0.31	−0.76	−1.23 *	similar to 6-phosphogluconate dehydrogenase


50 years +	Female	Male	Total

	N	%	n	%	N	%

Circulatory system diseases	29	27.6	19	18.6	48	23.2

Tuberculosis	7	6.7	10	9.8	17	8.2

Malaria	8	7.6	8	7.8	16	7.7

Intestinal infectious diseases (diarrhea)	3	2.9	6	5.9	9	4.3

Malignant neoplasms	5	4.8	3	2.9	8	3.9

Traffic accidents	2	1.9	5	4.9	7	3.4

Acute respiratory infections (pneumonia)	4	3.8	3	2.9	7	3.4

HIV	4	3.8	1	1.0	5	2.4

Diabetes Mellitus	1	1.0	4	3.9	5	2.4

Digestive system	1	1.0	3	2.9	4	1.9

Intentional self-harm	2	1.9	1	1.0	3	1.4

Accidental drowning and sub.	0	0.0	2	2.0	2	1.0

Rabies	1	1.0	0	0.0	1	0.5

Mental and behavioural disorders	0	0.0	1	1.0	1	0.5

Infections of the skin and subcutaneous tissue	0	0.0	1	1.0	1	0.5

Injury of unspecified body region	1	1.0	0	0.0	1	0.5

Exposure to unspecified electric current	1	1.0	0	0.0	1	0.5

Sepsis	0	0.0	1	1.0	1	0.5

Asthma	0	0.0	1	1.0	1	0.5

Unknow (R95-R99)	1	1.0	6	5.9	7	3.4

Indeterminate	35	33.3	27	26.5	62	30.0

Total	105		102		207

50 years +	Female

	N

Circulatory system diseases	29

Tuberculosis	7

Malaria	8

Intestinal infectious diseases (diarrhea)	3

Malignant neoplasms	5

Traffic accidents	2

Acute respiratory infections (pneumonia)	4

HIV	4

Diabetes Mellitus	1

Digestive system	1

Intentional self-harm	2

Accidental drowning and sub.	0

Rabies	1

Mental and behavioural disorders	0

Infections of the skin and subcutaneous tissue	0

Injury of unspecified body region	1

Exposure to unspecified electric current	1

Sepsis	0

Asthma	0

Unknow (R95-R99)	1

Indeterminate	35

Total	105


Device	Structure

A1	YIG/Ti/Co

A2	YIG/Ti/Co

A3	YIG/Ti/Co

A4	YIG/Al2O3/Co

B1	YIG/Ti/Ni

C1	YIG/Ti/CoFe

C2	YIG/Al2O3/CoFe


Sample

A-EtOH

A-BuOH

A-Water

A-EtOAc

A-Hexane

A-MeOH

AM1

AM2

AM3

AM4

AM5

AM6


Total clean reads

Total clean nucleotides

Total trinity transcripts

Total trinity components

Contig N50

Median contig length

Average contig

Total assembled bases

Percent GC (%)

Q20 percentage (%)


OD values	Biofilm formation

≤ODc	Non

2 × ODc ≤ OD > ODc	Weak

4 × ODc ≤ OD > 2 × ODc	Moderate

>4 × ODc	High

OD values

≤ODc

2 × ODc ≤ OD > ODc

4 × ODc ≤ OD > 2 × ODc

>4 × ODc

Biofilm formation

Non

Weak

Moderate

High


Scale	Subscale	 M	 SD	Extreme negative responders (%)a

Marcus	Prognosis for recovery (recovery)	3.01	1.37	—

Alcoholism and character defect (character defect)	2.59	1.22	—

Social status of the alcoholic (social status)	2.91	1.02	—

Alcoholism as an illness (illness)	3.13	1.67	4.2

Seaman-Mannello	Personal/professional satisfaction (satisfaction)	3.17	1.27	12.5

Inclination to identify (“helpable”)	4.17	.982	—

Personal attitudes toward drinking (personal drinking)	4.56	1.15	—

SAAPPQ	Work satisfaction (satisfaction)	3.66	1.11	8.2

Role adequacy	4.04	1.33	4.1

Role legitimacy	4.87	1.14	2.0

Task specific self-esteem (self-esteem)	4.96	1.22	16.7

I want to work with drinkers (desire)	3.40	1.23	14.3

Pessimism is the most attitude to take toward drinkers (pessimism)	2.85	1.40	2.0

Scale	Subscale	M	SD	Extreme negative responders (%)a

SAAPPQ	Pessimism is the most attitude to take toward drinkers (pessimism)	2.85	1.40	2.0


	Patients

	1	2	3	4

Management

Operation	No	Resection and IVC PTFE Patch	Resection and primary repair	Resection and IVC Vein Patch

Chemotherapy	Yes	No	No	No

Adjuvant therapy	None	Radiotherapy	None	Radiotherapy

Histological grade	High	High	High	High

Complications

Limb oedema	NA	No	No	No

Venous insufficiency	NA	No	No	No

Other	None	No	CVA	No

Follow-up

Recurrence	-	No	Yes (5 months)	No

Status	Dead	Dead	Dead	Alive

Survival	36 months	30 months	7 months	16 months

	Patients

	1	2	3

Management

Operation	No	Resection and IVC PTFE Patch	Resection and primary repair

Chemotherapy	Yes	No	No

Adjuvant therapy	None	Radiotherapy	None

Histological grade	High	High	High

Complications

Limb oedema	NA	No	No

Venous insufficiency	NA	No	No

Other	None	No	CVA

Follow-up

Recurrence	-	No	Yes (5 months)

Status	Dead	Dead	Dead

Survival	36 months	30 months	7 months

Patients

4

Resection and IVC Vein Patch

No

Radiotherapy

High

No

No

No

No

Alive

16 months


Baseline/outcome measure	Questionnaire	Survey administration times

Baseline	Time 1	Time 2

(after referral for abnormal screen)	(within 3 months ofnegativediagnosis)	(within 3 months ofpositivediagnosis)	(3 months after treatment initiation)

Health literacy	Rapid Estimate of Adult Literacy in Medicine[25]	X

Comorbid conditions that may alter risk of mortality	Charlson Comorbidity Index[24]	X

Anxiety and stress	Perceived Stress Scale[26]	X

Perceived functional support	Medical Outcomes Study-Social Support Survey[27]	X

Predisposition for fatalistic attitudes directed at health	Wallston Multi-Dimensional Locus of Control[28]	X	 	 	X

Distrust towards health care system	Health Care System Distrust[29]	X	X	 	X

Patient engagement in own health care	*Communication and Attitudinal Self-Efficacy - General[30]	 	X

Patient engagement in own cancer care	*Communication and Attitudinal Self-Efficacy - Cancer[30]	 	 	 	X

Subjective distress related to a specific event	*Impact of Events[31]	 	X	X	X

Satisfaction with cancer-related care	*Patient Satisfaction with Care[32]	 	X	X	X

Satisfaction with patient navigation services	Patient Satisfaction with Navigator[33]	 	X	X	X

Baseline/outcome measure	Questionnaire	Survey administration times

Baseline	Time 1	Time 2

(after referral for abnormal screen)	(within 3 months ofnegativediagnosis)	(within 3 months ofpositivediagnosis)	(3 months after treatment initiation)

Distrust towards health care system	Health Care System Distrust[29]	X	X		X

Patient engagement in own health care	*Communication and Attitudinal Self-Efficacy - General[30]		X

Patient engagement in own cancer care	*Communication and Attitudinal Self-Efficacy - Cancer[30]				X

Subjective distress related to a specific event	*Impact of Events[31]		X	X	X

Satisfaction with cancer-related care	*Patient Satisfaction with Care[32]		X	X	X

Satisfaction with patient navigation services	Patient Satisfaction with Navigator[33]		X	X	X


	Clusters

	The comprehensive	The theoretician	The minimalist	The structural

South American sample areas	14,1	7	31	47.9

European sample areas	24	49.5	25	1,5

Total	21.4	38.4	26.6	13.7


Resection margin	Recurrence rate No. patients (%)	Surgery and radiotherapy No. (%)	Surgery alone No. (%)

R0	5/16 (31)	2/4 (50)	3/12 (25)

R1	30/47 (64)	27/36 (75)	3/11 (27)


 	Phase	Morphology	Secondary phase

1,098 K/8 h

 Undoped	Rutile	Nanorod	-

 0.5% Co	Rutile	Nanorod	-

 1% Co	Rutile	Nanorod	-

 3% Co	Rutile	Nanorod	-

 5% Co	Rutile + anatase	Nanoparticle	-

 10% Co	Rutile	Nanoparticle + nanorod	CoTiO3 (nanoflakes)

1% Co-doped

 1,098 K/8 h	Rutile	Nanorod	-

 1,173 K/8 h	Rutile	Nanorod	-

 2 h/1,098 K	Rutile	Nanorod	-

 8 h/1,098 K	Rutile	Nanorod	-

 16 h/1,098 K	Rutile	Nanorod	-

5% Co-doped

 1,098 K/8 h	Rutile + anatase	Nanoparticle	-

 1,173 K/8 h	Rutile	Nanoparticle	-

 2 h/1,098 K	Rutile + anatase	Nanoparticle	-

 8 h/1,098 K	Rutile + anatase	Nanoparticle	-

 16 h/1,098 K	Rutile	Nanoparticle	Co2P4O12

	Phase	Morphology	Secondary phase

1,098 K/8 h

Undoped	Rutile	Nanorod	-

0.5% Co	Rutile	Nanorod	-

1% Co	Rutile	Nanorod	-

3% Co	Rutile	Nanorod	-

5% Co	Rutile + anatase	Nanoparticle	-

10% Co	Rutile	Nanoparticle + nanorod	CoTiO3 (nanoflakes)

1% Co-doped

1,098 K/8 h	Rutile	Nanorod	-

1,173 K/8 h	Rutile	Nanorod	-

2 h/1,098 K	Rutile	Nanorod	-

8 h/1,098 K	Rutile	Nanorod	-

16 h/1,098 K	Rutile	Nanorod	-

5% Co-doped

1,098 K/8 h	Rutile + anatase	Nanoparticle	-

1,173 K	R	Nano	-

	Phase	Morphology	Secondary phase

/8 h	utile	particle

2 h/1,098 K	Rutile + anatase	Nanoparticle	-

8 h/1,098 K	Rutile + anatase	Nanoparticle	-

16 h/1,098 K	Rutile	Nanoparticle	Co2P4O12


Question number	Question

1.	Please tell me all about your rotator cuff tear/shoulder? (follow up questions to find out when and and how the tear happened and obtain narrative history from participant).

2.	Please tell me about how your shoulder tear affected/affects you? (follow up questions to explore impact upon activities of daily living, work, leisure, relationships, emotional impact, and to explore symptoms).

3.	Are you right or left handed? (follow up to explore dominance, unilateral or bilateral shoulder problems, “how is your other shoulder?”).

4.	Please tell me anything else you’d like to tell me about your shoulder and how the tear had affected you?

Question

Please tell me all about your rotator cuff tear/shoulder? (follow up questions to find out when and and how the tear happened and obtain narrative history from participant).

Please tell me about how your shoulder tear affected/affects you? (follow up questions to explore impact upon activities of daily living, work, leisure, relationships, emotional impact, and to explore symptoms).

Are you right or left handed? (follow up to explore dominance, unilateral or bilateral shoulder problems, “how is your other shoulder?”).

Please tell me anything else you’d like to tell me about your shoulder and how the tear had affected you?


Generic name	Trade name	Number of cases of monotherapy

Losartan	Nu-lotan®	214

Valsartan	Diovan®	266

Telmisartan	Micardis®	185

Candesartan	Blopress®	458

Olmesartan	Olmetec®	192


Parameter	Level 1	Level 2	Level 3	Level 4	Level 5

100-OD (% sat.)	≤10	≤20	≤30	≤50	>50

BOD5 (O2 mg/L)	<2.5	≤4	≤8	≤15	>15

COD (O2 mg/L)	<5	≤10	≤15	≤25	>25

NH4 (N mg/L)	<0.03	≤0.10	≤0.50	≤1.50	>1.50

NO3 (N mg/L)	<0.3	≤1.5	≤5.0	≤10.0	>10.0

Total phosphorous (P mg/L)	<0.07	≤0.15	≤0.30	≤0.60	>0.60

Escherichia coli (UFC/100/mL)	<100	≤1.000	≤5.000	≤20.000	>20.000

Score to be attributed for each analysed parameter (75° percentile of the monitoring period)	80	40	20	10	5

Pollution level expressed by the LIM	480–560	240–475	120–235	60–115	<60

Parameter	Level 1	Level 2	Level 3	Level 4	Level 5

Escherichia coli (UFC/100/mL)	0	.000			0.000

Score to be attributed for each analysed parameter (75° percentile of the monitoring period)	80	40	20	10	5

Pollution level expressed by the LIM	480–560	240–475	120–235	60–115	<60


Re-revision diagnosis	UKA to UKA minor	UKA to UKA major	UKA to TKA	TKA to TKA

	n	%	n	%	n	%	n	%

Loosening/lysis	17	46	27	52	63	46	34	42

Infection	2	5.4	5	9.6	19	14	25	31

Pain	6	16.2	6	11.5	18	13	8	9.9

Patello femoral pain	1	2.7	1	1.9	9	6.5	3	3.7

Progression of disease	2	5.4	7	14	3	2.2

Other	9	24.3	6	12	26	19	11	13

Total	37	100	52	100	138	100	81	100

Re-revision diagnosis	UKA to UKA minor	UKA to UKA major	UKA to TKA	TKA to TKA

	n	%	n	%	n	%	n	%

Pain	6	16.2	6	11.5	18	13	8	9.9

Patello femoral pain	1	2.7	1	1.9	9	6.5	3	3.7

Progression of disease	2	5.4	7	14	3	2.2

Other	9	24.3	6	12	26	19	11	13

Total	37	100	52	100	138	100	81	100


Diagnosis in MRI	Specific abnormalities in MRI	N	Total number (%)

Abnormal MRI	 	 	13 (52%)

Hepatic dysmorphia	Included lobulation of liver surface	3	3 (12%)

Included first-segment hypertrophy	0

Portal hypertension	Included splenomegaly	5	5 (20%)

Included portal vein dilatation	2

Included splenic vein dilatation	1

Isolated biliary abnormalities	Intrahepatic	1	1 (4%)

Extrahepatic	0

Hepatic dysmorphia and portal hypertension	 	0	0 (0%)

Hepatic dysmorphia and biliary abnormalities	Included lobulation of liver surface and intrahepatic abnormalities	1	1 (4%)

Portal hypertension and biliary abnormalities	Included portal vein hypertrophy and intrahepatic abnormalities	1	1 (4%)

Hepatic dysmorphia, portal hypertension, and biliary abnormalities	Included splenomegaly, lobulation of liver surface, first-segment hypertrophy, and intrahepatic and extrahepatic abnormalities	2	2 (8%)

Normal MRI	 	 	12 (48%)

Total 	 	 	25 (100%)

Diagnosis in MRI	Total number (%)

Total	25 (100%)


Variable	OR [95%CI]	P value

Steroids before ICU stay	0.77 [0.17-3.49]	0.74

Steroids during ICU stay

No Steroid	5.64 [0.70-45.5]

Low Dose Steroid	1	0.02

High Dose Steroids	9.33 [1.97-44.3]

SAPS II per point	1.04 [1.01-1.08]	0.01

Underlying disease

Hematological disease	1

Other	4.06 [1.19-13.09]	0.03

Shock	20.31 [6.45-63.9]	<0.001

Variable	OR [95%CI]	P value

Steroids before ICU stay	0.77 [0.17-3.49]	0.74

Steroids during ICU stay

No Steroid	5.64 [0.70-45.5]

Low Dose Steroi	1


	Male

C

Dietary component

Energy (kJ)	9665

Nutrients

Carbohydrates (%E)	42.8

Total Sugars (%E)	18.1

Free Sugar (%E)	9.2

Total Fat (%E)	30.5

Saturated Fat (%E)	11.9

MUFA (%E)	11.8

PUFA (%E)	4.7

Protein (%E)	19.5

Sodium (mg)	2838

Fibre (%E)	2.2

Food Groups

Discretionary Foods (%E)	33.7

Grains and Cereals (serves)	5.0

Meat and Alternatives (serves)	2.2

Dairy and alternatives (serves)	1.7

Fruit (serves)	1.7

Vegetables (serves)	2.9


Variablea	HR (95% CI)	P

Bowel obstruction/perforation (positive vs negative)	4.118 (2.270-7.471)	<.001

Lymphovascular invasion (positive vs negative)	1.766 (1.156-2.697)	.009

Five-gene molecular signature (high-risk vs low-risk for 36-mo recurrence)	1.644 (1.035-2.610)	.035

Variablea	HR (95% CI)	P

Lymphovascular invasion (positive vs negative)	1.766 (1.156-2.697)	.009

Five-gene molecular signature (high-risk vs low-risk for 36-mo recurrence)	1.644 (1.035-2.610)	.035


Subject	R (mean ± std. deviation)

1	0.8084 ± 0.0140


% Coronary Vasoreactive Change with IHE vs. Coronary Wall Measure:	% area change	% velocity change	% flow change

Healthy: Mean Coronary Wall Thickness	R = -0.17	R = 0.02	R = -0.02

P = 0.46	P = 0.93	P = 0.92

Healthy: Eccentricity Index	R = 0.18	R = 0.08	R = 0.14

P = 0.46	P = 0.74	P = 0.56

CAD: Mean Coronary Wall Thickness	R = -0.54	R = -0.11	R = -0.34

P = 0.001	P = 0.51	P = 0.05

CAD: Eccentricity Index	R = -0.60	R = -0.06	R = -0.27

P = 0.0002	P = 0.75	P = 0.13

% Coronary Vasoreactive Change with IHE vs. Coronary Wall Measure:	% area change	% velocity change	% flow change

Healthy: Eccentricity Index	P = 0.46	P = 0.74	P = 0.56

CAD: Mean Coronary Wall Thickness	R = -0.54	R = -0.11	R = -0.34

P = 0.001	P = 0.51	P = 0.05

CAD: Eccentricity Index	R = -0.60	R = -0.06	R = -0.27

P = 0.0002	P = 0.75	P = 0.13


	GOLD II	GOLD III	GOLD IV	Total

	(n = 12)	(n = 21)	(n = 10)	(n = 43)


Adipokine

Adipsin

MCP-1

IL-1β

IP-10

CXCL8

IL-6

Resistin

TNF-α


Grade	Normal group	Osteoarthritis group

	12 F	39 F	43 M	42 M	49 F	54 F	55 M	58 F	65 F	66 F	70 F

Transverse section	0	0	0	2	2	3	3	1	3	4	4

Longitudinal section	0	0	0	3	1	3	3	1	4	4	4

Averagea	0	0	0	2.5	1.5	3	3	1	3.5	4	4

Grade	Normal group	Osteoarthritis group

	12 F	39 F	43 M	42 M	49 F	54 F	55 M	58 F	65 F	66 F	70 F

Transverse se	0		0	2	2		3	1	3		4

ction		0				3				4

Longitudinal section	0	0	0	3	1	3	3	1	4	4	4

Averagea	0	0	0	2.5	1.5	3	3	1	3.5	4	4


Variable	Comparison used in rate ratio	Rate ratio (other death/HIV/TB death)	95% Confidence interval (p value)

Sex	Male/female	1.12	0.99–1.27 (0.077)

Country of origin	South Africa/Mozambique	0.85	0.75–0.98 (0.023)

Residence status	Temporary/permanent	1.05	0.91–1.21 (0.493)

Distance from Bhubezi(km)	Greater than 5 km/5 km or less	1.02	0.86–1.20 (0.842)

SEP quintiles	Quintiles 2–5/quintile 1	0.95	0.81–1.11 (0.503)

Mean level of household education	Greater than 7 years/7 years or less	0.93	0.82–1.06 (0.294)


ABRA system delayed closure system

Pros	Cons

ABRA abdominal wall closure can restore lost abdominal domain and achieve complete repair of the musculofascial support of the abdominal wall, achieving primary closure. The sutures can be tightened at sequential dressings, preventing fascial retraction	ABRA abdominal wall closure requires two to three interventions in operation room under general anesthesia

No skin grafts required when using ABRA	ABRA system need a normal skin of 5–6 cm around the abdominal wound (in order to place the elastomers)

Reduction in the numbers of days to any closure	The possibility to need to be used in conjunction with another dressing system

The changes of VAC system and time in nurse and surgery cares are more expensive than ABRA system	There is no active removal of the fluids. So if the peritonitis is still active a dressing system with 24–48 h re-interventions could be the best option

ABRA system delayed closure system

Pros	Cons

ABRA abdominal wall closure can restore lost abdominal domain and achieve complete repair of the musculofascial support of the abdominal wall, achieving primary closure. The sutures can be tightened at sequential dressings, preventing fascial retraction	ABRA abdominal wall closure requires two to three interventions in operation room under general anesthesia

No skin grafts required when using ABRA	ABRA system need a normal skin of 5–6 cm around the abdominal wound (in order to place the elastomers)

Reduction in the numbers of days to any cl	T

osure	he possibility to need to be used in conjunction with another dressing system

The changes of VAC system and time in nurse and surgery cares are more expensive than ABRA system	There is no active removal of the fluids. So if the peritonitis is still active a dressing system with 24–48 h re-interventions could be the best option


Study characteristics	Nepal trial*	Bangladesh trial	Pakistan trial

Type of study	Cluster RCT	Cluster RCT	2 × 2 factorial design cluster RCT

No. clusters (average size)	413 (700)	133 (4100)	187 (1000)

Sample size total	15,123	29,760	9,741

Average sample size per group	~ 5,050	~ 9,900	~ 4,850

Duration of trial	Nov 2002 to Mar 2005	Jun 2007 to Sep 2009	Jan 2008 to Jun 2009

Overall NMR	32/1000	36/1000	30/1000

% of home births	92 %	93 %	80 %

Inclusion criteria	All live births in the study area	All live births in the study area	All live births in the study area were included except those who were born in hospitals.

Exclusion criteria	Not met within 10 days after birth	Didn’t receive intervention within 7 days after birth	Not met within 3 days after birth. Babies with congenital anomalies

Comparison group	Dry cord care	Dry cord care	Dry cord care

Intervention groups	1.Multiple CHX2.Soap/H2O	1.Multiple CHX2.Single CHX	1.Multiple CHX2.Handwashing (HW)3.CHX + HW

CHX concentration	4.0 %	4.0 %	4.0 %

Participants recruiters	Local female worker	CHWs	CHWs

Intervention providers	Local project staff	Village health worker	TBA to caretaker

Outcome assessors	(Nonmedical) field workers	CHWs	CHWs

Basic interventions to all babies/mothers	CDK, FE/FA, TT, promotion of ANC/ENC	CDK. FE/FA, promotion of TT, ANC, birth preparedness, ENC	Basic component of ENC as promoted by Ministry of Health

Primary outcomes	Omphalitis, neonatal mortality	Omphalitis, neonatal mortality	Omphalitis, neonatal mortality

Follow up days	1, 2, 3, 4, 6, 8, 10, 12, 14, 21, 28	1,3,6,9,15,28	1,3,5,7,14,28

Study characteristics

Type of study

No. clusters (average size)

Sample size total

Average sample size per group

Duration of trial

Overall NMR

% of home births

Inclusion criteria

Exclusion criteria

Comparison group

Intervention groups

CHX concentration

Participants recruiters

Intervention providers

Outcome assessors

Basic interventions to all babies/mothers

Primary outcomes

Follow up days

Nepal trial*	Bangladesh trial	Pakistan trial

Cluster RCT	Cluster RCT	2 × 2 factorial design cluster RCT

413 (700)	133 (4100)	187 (1000)

15,123	29,760	9,741

~ 5,050	~ 9,900	~ 4,850

Nov 2002 to Mar 2005	Jun 2007 to Sep 2009	Jan 2008 to Jun 2009

32/1000	36/1000	30/1000

92 %	93 %	80 %

All live births in the study area	All live births in the study area	All live births in the study area were included except those who were born in hospitals.

Not met within 10 days after birth	Didn’t receive intervention within 7 days after birth	Not met within 3 days after birth. Babies with congenital anomalies

Dry cord care	Dry cord care	Dry cord care

1.Multiple CHX2.Soap/H2O	1.Multiple CHX2.Single CHX	1.Multiple CHX2.Handwashing (HW)3.CHX + HW

4.0 %	4.0 %	4.0 %

Local female worker	CHWs	CHWs

Local project staff	Village health worker	TBA to caretaker

(Nonmedical) field workers	CHWs	CHWs

CDK, FE/FA, TT, promotion of ANC/ENC	CDK. FE/FA, promotion of TT, ANC, birth preparedness, ENC	Basic component of ENC as promoted by Ministry of Health

Omphalitis, neonatal mortality	Omphalitis, neonatal mortality	Omphalitis, neonatal mortality

1, 2, 3, 4, 6, 8, 10, 12, 14, 21, 28	1,3,6,9,15,28	1,3,5,7,14,28


	WHO guidelinea	Swiss TPH guidelinea

	Trichuris trichiura	Ascaris lumbricoides	Trichuris trichiura	Ascaris lumbricoides

Total number of Kato-Katz thick smears (positive/negative)	1,445 (1,189/256)	1,445 (297/1,148)	1,445 (1,189/256)	1,445 (297/1,148)

1. No. of Kato-Katz thick smears with difference in FECs (%)	345 (23.9%)	148 (10.2%)	97 (6.7%)	108 (7.5%)

2. No. of Kato-Katz thick smears with differences in presence/absence of helminth eggs (%)	51 (3.5%)	32 (2.2%)	51 (3.5%)	32 (2.2%)

3. No. of Kato-Katz thick smears with difference in FECs (%) among samples with egg counts	345 (29.0%)	148 (49.8%)	97 (8.2%)	108 (36.4%)

4. No. of Kato-Katz thick smears with differences in presence/absence of helminth eggs (%) among samples with egg counts	51 (4.3%)	32 (10.8%)	51 (4.3%)	32 (10.8%)

1. and/or 2. (%)	381 (26.4%)	164 (11.4%)	145 (10.0%)	130 (9.0%)

No. of Kato-Katz thick smears with discrepancies according to respective guidelineb (%)	345 (23.9%)	164 (11.4%)	145 (10.0%)	130 (9.0%)

3. and/or 4. and proportion as percentage (%) among Kato-Katz thick smears with positive egg counts	381 (32.0%)	164 (55.2%)	145 (12.2%)	130 (43.8%)

No. of Kato-Katz thick smears with discrepancies according to respective guidelineb (%) among Kato-Katz thick smears with positive egg counts	345 (29.0%)	148 (49.8%)	145 (12.2%)	130 (43.8%)


Biologics	Pooled incremental efficacy	6-month incremental cost-effectiveness ratio

Base case	Best case 	Worst case	Base case	Best case	Worst case

Etanercept	58%	71%	45%	$30,954	$25,287	$39,897

Adalimumab	56%	59%	52%	$23,980	$22,760	$25,824

Infliximab	69%	76%	63%	$28,587	$25,954	$31,310

Ustekinumab 45 mg	58%	64%	51%	$28,943	$26,229	$32,915

Ustekinumab 90 mg	62%	66%	58%	$54,151	$50,869	$57,886

Biologics	Pooled incremental efficacy

Base case	Best case	Worst case

Etanercept	58%	71%	45%

Adalimumab	56%	59%	52%

Infliximab	69%	76%	63%

Ustekinumab 45 mg	58%	64%	51%

Ustekinumab 90 mg	62%	66%	58%


	All suicide	Firearm suicide	Nonfirearm suicide

	IRR*	95% CI	P-value	IRR*	95% CI	P-value	IRR*	95% CI	P-value


 	Low-income countries	Middle-income countries	High-income countries

Number of global countries where data is < 5% gross monthly income	5	78	46

% of subscriptions with broadband speeds 10 mbps or higher	7	50	75


Variable	RBHS group (n = 36)	Control group (n = 38)	Pvalue

Composite outcome (any morbid event)	1 (2.8)	5 (13.1)	0.20

Morbid eventsa

Infection	0 (0%)	1 (2.8%)	0.20

Thrombotic	1 (2.8%)	2 (5.3%)	0.87

Renal	1 (2.8%)	2 (5.3%)	0.87

Respiratory	0 (0%)	0 (0%)	NS

Stroke	0 (0%)	0 (0%)	NS

Myocardial infarction	0 (0%)	0 (0%)	NS


Country	Acronym of the Study	Year of Recruitment	Age Class	n	GM	50p	95p	Reference

USA	NHANES	2009–20102011–2012	>20 years	20201724	6.75.6	5.955.15	23.217.6	[57]


Function	Gene	Accession no.∗	Chromosome

			T. aestivum	Ae. umbellulata

Protein biosynthesis

HMW glutenins	Glu-1Ax1	X61009	1A	1U

	Glu-1Ax2	M22208.2	1A	1U

	Glu-B1-1b	X13927.3	1B	1U

	Glu-1D-1d	X12928.5	1D	1U

	Glu-D1-2b	X12929.2	1D	1U

		X03041.1	1D	1U

	Glu-1Ux	AF476961.1	–	1U

	Glu-1Uy	AF476962.1	–	1U

LMW glutenins		AB062868.1	1D	1U

		AB062872.1	1D	1U

		JX163862.1	1B	1U

		HM055909.1	1DS	1U

		Y17845.1	1BS	1U

		U86026.1	1DS	1U

		X13306.1	1DS	1U

		AB062875.1	1DS	1U

		U86028.1	1DS	1U

		X07747.1	1AS	1U

		AB062873.1	1DS	1U


	RDP (n = 7)	LDP (n = 21)	P value

Mean operative time (min)	368	210	0.0002

Mean blood loss (mL)	200	250	0.451

Transfusion (no. of patients) (%)	0	0

Conversion (no. of patients) (%)	0	0

Reverse operation (no. of patients) (%)	0	1 (4.7)a

Mean postoperative stay (days)	8.7	10.6	0.004

Complications (no. of patients) (%)	2 (28.6)	7 (33.3)	0.815

Grade, Clavien classification	II (1), III (1)	I (5), II (1), III (1)

Hospital costs ($)	10,125	6921	0.0002


Group	Drug	Frequency	Percent (n/N) b

β-lactam		26	28.9 (26/90)

 Penicillin	PenicillinG	11	29.0 (11/27)

	Ampicillin	12	32.4 (12/26)

 Cephalosporin	Cephalothin	1	2.7 (1/37)

	Ceftiofur	1	2.7 (1/37)

 Combination	Amoxicillin/Clavulanic acid	1	2.7 (1/37)

Tetracycline	Doxycycline	1	2.7 (1/37)

Fluoroquinolone		6	8.6 (6/70)

	Enrofloxacin	3	7.9 (3/35)

	Orbifloxacin	3	7.9 (3/35)

Aminoglycoside		4	3.6 (4/110)

	Gentamicin	1	2.7 (1/37)

	Amikacin	1	2.7 (1/37)

	Kanamycin	2	5.3 (2/36)

Potentiated sulfonamide	Sulfamethoxazole/trimethoprim	4	10.5 (4/34)

Amphenicols	Chloramphenicol	2	5.2 (2/36)

Lincosamides	Clindamycin	13	34.2 (13/25)

Aminoglycoside-lincosamide	Lincospectin	12	31.6 (12/26)

Macrolide	Tylosin	2	5.3 (2/36)


Group	Dose (mg/kg)	Mean Fasting Blood Sugar Level (mM)

0 min	30 min	60 min	120 min

NC	–	4.32 ± 0.88	13.65 ± 1.24	8.94 ± 1.47	4.89 ± 0.95


Predictor	1 year	2 years

Unadjusted OR (95% CI)	p Value	Adjusted OR (95% CI)	p Value	Unadjusted OR (95% CI)	p Value	Adjusted OR (95% CI)	p Value

HAQ score	1.84 (1.12 to 3.01)	0.02	1.87 (1.11 to 3.15)	0.02	1.47 (0.94 to 2.29)	0.09	1.42 (0.89 to 2.26)	0.14

Predictor	1 year	2 years

Unadjusted OR (95% CI)	p Value	Adjusted OR (95% CI)	p Value	Unadjusted OR (95% CI)	p Value

HAQ score	1.84 (1.12 to 3.01)	0.02	1.87 (1.11 to 3.15)	0.02	1.47 (0.94 to 2.29)	0.09

2 years

Adjusted OR (95% CI)	p Value

1.42 (0.89 to 2.26)	0.14


Study Cohort	Number	Percentages

Women	36	34

Men	71	66

Mean Age 64.7 years

(Range 31–95 years)

Clinical Neuropathic Syndrome

MNM	1	1

DLRPN	35	33

DSPN	71	66

Histological Severity of Neuropathy

Normal	1	1

Mild	17	16

Moderate	54	50

Severe	35	33

Teased Fiber/Semithin Section Analysis

Normal	1	1

Axonopathy	45	65

Myelinopathy	23	35

Cellular Response

Perivasculitis	26	23

Microvasculitis	3	3

Necrotizing arteritis	3	3

Complement Immunofluorescence

C3 deposition	70	67

C5b-9	65	62

Other Findings

Onion bulb formation	10	9

Epineurial vascular thrombosis	5	5


Type	Strain/ Transgeneb	Main patternc	Myoepithelial differentiationd	EMT (%)e	K1	K5	K6	K8/18	K10	K14	K17	FLG	IVL	LOR	THH	SMA	VIM

Simple	FVB-Myc	Glandular	6/9	4/9 (<1%)		+	+	+		++	+

	FVB-Notch4	Glandular	0/6	0				+		+	+

	C57BL6/J-Tag	Glandular	1/5	0				+		+	+

	BALB/cJ (mostly)	Papillary, 1 cell thick	2/6	0		+	+	++		++	++

	C57BL6/J-Tag	Papillary	0/4	0				+		+	+

	FVB-Myc	Solid	1/4	3/4 (<1%)				+		+	+

	FVB-Neu	Solid	0/10	0

Complex	FVB and B6D2-Tgfa	Macrocyst	6/8	0		+	+	+++		+	+					+

	FVB and B6D2-Tgfa	Lactation plaque	3/3	0		++	+	+++		++	+					+

	BALB/cJ	Adenomyoepithelioma	5/5	0	+	+++	++	++		+++	++

	BALB/cJ (mostly)	Adenoacanthoma	7/7	0	++	++	++	++	++	+++	+++	++	++	+	+	+

	C3H/HeJ	Microacinar	8/8	0		++	+	++		++	+

	BALB/cJ, C3H/HeJ	Papillary, 2 cells thick	2/2	0		++		++	+	++	++					+++

	C3H/HeJ	Type P tumor	9/9	0		++	+	++		++	++		+			+++

	FVB-Wnt1	Type P tumor	6/6	0		++	++	+++		++	++	+	+			++

	B6SJL-Wnt1	Type P tumor	7/7	0		+	+	+		++	+					++

EMT	C57BL6/J-Tag	Glandular with EMT	2/3	3/3 (6%)				+++		+++	++					++	+

	FVB-Myc	Glandular with EMT	4/6	6/6 (20%)		+	+	++		++	++					+	+

	PL/J and SJL/J	Glandular with EMT	4/4	4/4 (38%)		++	+	+++		++	++		+			++	++

	FVB-Hras	Solid with EMT	3/4	3/4 (<1%)		+		++		+	+						+

Strain/ Transgeneb	Main patternc	Myoepithelial differentiationd	EMT (%)e	K5	K8/18	K14	K17	VIM

FVB-Hras	Solid with EMT	3/4	3/4 (<1%)	+	++	+	+	+


EORTC QLQ-C30 subscales	Item	Baseline	2 weeks post-RT

		IG (n = 89)	CON (n = 89)			IG (n = 89)	CON (n = 89)

		Mean(SD)	Mean(SD)	tvalue	pvalue	Mean(SD)	Mean(SD)	tvalue	pvalue*


Category	All Respondents (n = 769)

1 Lack of timea	33.0% (254)

2 Behaviours attributed to women living with abuse	21.5% (165)

3 Lack of traininga	16.4% (126)b

4 Language/cultural practicesa	15.5% (119)c

5 Partner presencea	14.0% (108)

6 Lack of resourcesa	13.0% (100)

7 Lack of space/privacya	8.2% (63)

8 Discomfort with topic	4.6% (35)

9 Lack of practitioner knowledge of resources	2.6% (20)


CHEK2 mutation type	Controls(n = 1,026)a	Allelic frequency in controls	Cases(n = 1,014)a	Allelic frequency in cases	P value	OR	95% CI

Any CHEK2 mutation	4	0.39%	16	1.58%	0.0065	4.15	(1.38 to 12.50)

CHEK2 deleterious mutations	3	0.29%	15	1.48%	0.0042	5.18	(1.49 to 18.00)

CHEK2 mutation type

Any CHEK2 mutation

CHEK2 deleterious mutations


Polysaccharide(s)	Source(s)	Animals	Dose/day	Duration	CNS tests performed	Significant effects	Reference

Alpha-glucan (isolichenan)	Cetrariella islandica	5-week-old ♂ Std-ddY mice treated with 30% ethanol p.o. 20 minutes before learning trial	100, 200, or 400 mg/kg p.o. once	30 minutes before learning trial	Passive avoidance step through and step down	All doses reversed ethanol impaired fear memory acquisition; no effects on mice without ethanol exposure	18

♂ Wistar rats receiving daily i.c.v. injections of A-beta peptide from day 7 to day 4	100 or 200 mg/kg p.o.	8 days	Morris water maze	100 mg/kg reversed A-beta-induced spatial memory deficits; no effects on rats without A-beta peptide pretreatment	18

Arabinoxylan; beta-glucan	Triticum aestivum L.; Hordeum vulgare L.	♂ Sprague–Dawley rats with bilateral common carotid artery occlusion	20 mg/kg p.o.	Days 8–14 post-surgery; testing on days 22–26 post-surgery	Morris water maze; immunohistochemistry and western blot (GFAP, MBP); Luxol fast blue and hematoxylin staining	Both treatments reversed ischemia-induced spatial memory deficits; arabinoxylan prevented loss of MBP in corpus callosum	20

Pectin	Citrus [peel]	9–11-week-old C56BL/6J mice injected i.p. with 100 μg/kg LPS	10% pectin diet	6–8 weeks post-weaning	Social exploratory behavior of a novel juvenile mouse	Faster recovery from LPS-induced social withdrawal compared with 5% cellulose diet	19

Polysaccharide fraction: PSF (no characterization provided)	Panax ginseng	Adult ♂ Wistar rats	4, 20, or 40 mg/kg i.p.	10 days	Conditioned Active Escape Response	All doses differentially improved indications of learning and memory	22

Alpha-glucan (FPS)	Fu Zi (Aconitum carmichaeli Debx)	8–11-week-old ♂ C57BL/6 mice	5 to 400 mg/kg i.p.	Varied with assay: 30 minutes, 6 hours, or 1–4 weeks	BrdU labeling; forced swim; open-field; novelty-suppressed feeding; chronic social defeat stress; monoamine levels in the frontal cortex; ELISA and Western blot (BDNF)	10–400 mg/kg doses increased newborn neurons in the DG; 50 and 100 mg/kg produced AD effects (similar to imipramine); 100 mg/kg increased BDNF expression in the hippocampus; AD and neurogenesis effects were blocked by co-injection with K252a (trkB inhibitor)	23

Polysaccharide(s)

Alpha-glucan (isolichenan)

Arabinoxylan; beta-glucan

Pectin

Polysaccharide fraction: PSF (no characterization provided)

Alpha-glucan (FPS)

Source(s)	Animals	Dose/day	Duration	CNS tests performed	Significant effects	Reference

Cetrariella islandica	5-week-old ♂ Std-ddY mice treated with 30% ethanol p.o. 20 minutes before learning trial	100, 200, or 400 mg/kg p.o. once	30 minutes before learning trial	Passive avoidance step through and step down	All doses reversed ethanol impaired fear memory acquisition; no effects on mice without ethanol exposure	18

♂ Wistar rats receiving daily i.c.v. injections of A-beta peptide from day 7 to day 4	100 or 200 mg/kg p.o.	8 days	Morris water maze	100 mg/kg reversed A-beta-induced spatial memory deficits; no effects on rats without A-beta peptide pretreatment	18

Triticum aestivum L.; Hordeum vulgare L.	♂ Sprague–Dawley rats with bilateral common carotid artery occlusion	20 mg/kg p.o.	Days 8–14 post-surgery; testing on days 22–26 post-surgery	Morris water maze; immunohistochemistry and western blot (GFAP, MBP); Luxol fast blue and hematoxylin staining	Both treatments reversed ischemia-induced spatial memory deficits; arabinoxylan prevented loss of MBP in corpus callosum	20

Citrus [peel]	9–11-week-old C56BL/6J mice injected i.p. with 100 μg/kg LPS	10% pectin diet	6–8 weeks post-weaning	Social exploratory behavior of a novel juvenile mouse	Faster recovery from LPS-induced social withdrawal compared with 5% cellulose diet	19

Panax ginseng	Adult ♂ Wistar rats	4, 20, or 40 mg/kg i.p.	10 days	Conditioned Active Escape Response	All doses differentially improved indications of learning and memory	22

Fu Zi (Aconitum carmichaeli Debx)	8–11-week-old ♂ C57BL/6 mice	5 to 400 mg/kg i.p.	Varied with assay: 30 minutes, 6 hours, or 1–4 weeks	BrdU labeling; forced swim; open-field; novelty-suppressed feeding; chronic social defeat stress; monoamine levels in the frontal cortex; ELISA and Western blot (BDNF)	10–400 mg/kg doses increased newborn neurons in the DG; 50 and 100 mg/kg produced AD effects (similar to imipramine); 100 mg/kg increased BDNF expression in the hippocampus; AD and neurogenesis effects were blocked by co-injection with K252a (trkB inhibitor)	23


Characteristic	HES APCa	Englandb

Finished consultant episodes	18731964

Admissions	15892434

Admission type

Emergency	5615707 (30.0)

Waiting list	6119234 (32.7)


miRNAs	Expression in lung cancer	Cellular processes affected and targets	Reference

Let-7 family	Decreased	(i) Cell proliferation (KRAS, MYC, and HMGA2)	[28–30]

(ii) miRNA maturation Dicer mediated	[31]

(iii) Cell-cycle regulation (CDC25A, CDK6, and cyclin D2)	[32]

mir-34 family	Decreased	(i) Transcriptionally activated by p53	[40]

(ii) TRAIL-induced cell death and cell proliferation (BCL-2, MET, and PDGFR-α/β)	[41–43]

mir-21	Increased	(i) Apoptosis, cellular proliferation, and migration (TPM1, PDCD4, and PTEN)	[50–53]

(ii) TKI-treatment resistance	[54]

mir-17/92a cluster	Increased	(i) Transcriptionally regulated by c-MYC	[60]

(ii) Cellular proliferation and cancer development (PTEN, HIF-1a CL2L11, CDKNA, and TSP-1)	[57, 61–63]

mir-15a/16 cluster	Decreased	Cell cycle regulation (cyclin D1, D2 and E1)	[66, 67]

mir-200 family	Decreased	Promotion of EMT and metastasization(ZEB transcription factors,CDH-1, and vimentin)	[68–73]

miRNA-29 family	Decreased	Epigenetic regulation of gene expression (DNMT-3A and DNMT-3B)	[74]

mir-221/mir-222	Increased	(i) TRAIL resistance and cellular migration (PTEN and TIMP3)	[75, 76]

(ii) Transcriptionally regulated by EGFR and MET and gefitinib resistance (BIM and APAF1)	[77]

mir-548	Decreased	Tumor cell growth (CCND, ERBB2, DMNT3A, and DNMT3B)	[78]

miRN	Expression in lun	Cellular processes affe	Refe

As	g cancer	cted and targets	rence

Let-7 family	Decreased	(i) Cell proliferation (KRAS, MYC, and HMGA2)	[28–30]

(ii) miRNA maturation Dicer mediated	[31]

(iii) Cell-cycle regulation (CDC25A, CDK6, and cyclin D2)	[32]

mir-34 family	Decreased	(i) Transcriptionally activated by p53	[40]

(ii) TRAIL-induced cell death and cell proliferation (BCL-2, MET, and PDGFR-α/β)	[41–43]

mir-21	Increased	(i) Apoptosis, cellular proliferation, and migration (TPM1, PDCD4, and PTEN)	[50–53]

(ii) TKI-treatment resistance	[54]

mir-17/92a cluster	Increased	(i) Transcriptionally regulated by c-MYC	[60]

(ii) Cellular proliferation and cancer development (PTEN, HIF-1a CL2L11, CDKNA, and TSP-1)	[57, 61–63]

mir-15a/16 cluster	Decreased	Cell cycle regulation (cyclin D1, D2 and E1)	[66, 67]

mir-200 family	Decreased	Promotion of EMT and metastasization(ZEB transcription factors,CDH-1, and vimentin)	[68–73]

miRNA-29 family	Decreased	Epigenetic regulation of gene expression (DNMT-3A and DNMT-3B)	[74]

mir-221/mir-222	Increased	(i) TRAIL resistance and cellular migration (PTEN and TIMP3)	[75, 76]

(ii) Transcriptionally regulated by EGFR and MET and gefitinib resistance (BIM and APAF1)	[77]

mir-548	Decreased	Tumor cell growth (CCND, ERBB2, DMNT3A, and DNMT3B)	[78]


	SL2 clinical data	SL1 clinical data	p-value

	Pre 24 hour	Pilot trial (+)	Post 24 hour	Pilot trial (+)	SL1 vs. SL2

Number of patients:	9	9	9	9	/

Total hours:	/	194 h	/	215 h	/

Number of BG measurements:	46	91	44	205	/

BG median [IQR] (mg/dL):	155.5 [124.0 - 171.0]	134.0 [117.2 - 150.8]	136.5 [115.0 - 159.5]	136.0 [122.5 - 158.0]	0.27(*)

% BG within 80–100 mg/dL	8.7	3.3	6.82	3.4	1.00


Fatty acid	Name	Percentage in EVOO	mg FAME/g sample

C16:0	Palmitic acid	11,27	125,41

C16:1n7	Palmitoleic acid	0,86	9,56

C17:0	Margaric acid	0,04	0,46

C18:0	Stearic acid	3,85	42,81

C18:1n7c	Cis-Vaccenic acid	2,42	26,92

C18:1n9c	Oleic acid	75,99	845,97

C18:2n6c	Linoleic acid	4,2	46,74

C18:3n3	α-Linolenic acid	0,61	6,81

C20:0	Arachidic acid	0,4	4,46

C20:1n9	Cis-11 eicosenoic acid	0,22	2,42

C22:0	Behenic acid	0,1	1,14

C24:0	Lignoceric acid	0,05	0,544

Selected phenolic compounds (STP)			μg/g sample

Hydroxytyrosol			9,31

p-coumaric acid			0,14

Oleuropein			n.d.

Fatty acid	Name

C16:0	Palmitic acid

C16:1n7	Palmitoleic acid

C17:0	Margaric acid

C18:0	Stearic acid

C18:1n7c	Cis-Vaccenic acid

C18:1n9c	Oleic acid

C18:2n6c	Linoleic acid

C18:3n3	α-Linolenic acid

C20:0	Arachidic acid

C20:1n9	Cis-11 eicosenoic acid

C22:0	Behenic acid

C24:0	Lignoceric acid

Selected phenolic compounds (STP)

Hydroxytyrosol

p-coumaric acid

Oleuropein


Covariate	χ2	P-value	Hazard ratio	95% CI

Adjacent involvement (with vs. without)	11.841	0.001	2.295	1.430-3.683

Mitotic rate (> = 5/50 HPF vs. <5/50 HPF)	8.895	0.003	2.406	1.351-4.284

Risk grade (high risk vs. non-high risk)	26.129	<0.001	11.794	4.579-30.379

Covariate	χ2	P-value	Hazard ratio	95% CI

Adjacent involvement (with vs. without)	11.841	0.001	2.295	1.430-3.683

	8.89	0	2.40	1


 	Validation against our test	Validation against the test in literature

 	The current experiment (n = 8)	Predicted value	Hashemi et al.’s experiment (n > 4)	Predicted value

High density	2015 ± 95.7 N	2028.8 N	2132.5 ± 119.3 N	2028.8 N

Low density	657 ± 69.4 N	607 N	688.2 ± 91.4 N	607 N

	Validation against our test	Validation against the test in literature

	The current experiment (n = 8)	Predicted value	Hashemi et al.’s experiment (n > 4)

High density	2015 ± 95.7 N	2028.8 N	2132.5 ± 119.3 N

Low density	657 ± 69.4 N	607 N	688.2 ± 91.4 N

Validation against the test in literature

Predicted value

2028.8 N

607 N


	n	%

Gender

 Male	432	49.3

 Female	444	50.7

Ethnicity

 White	536	61.2

 Non-white	340	38.8

Education

 Less than college	421	48.1

 Some college or higher	455	51.9

Household income

 Less than $20,000	506	57.8

 $20,000 or more	370	42.2

Marital status

 Single	665	75.9

 Married/living with partner	211	24.1

Insurance

 Managed care (HMO, PPO)	241	27.5

 Medicare	364	41.6

 Veterans Affairs Medical Center	41	4.7

 State Medicaid (MediCal for CA residents)	350	40.0

 No health insurance	61	7.0

 Don't know	16	1.8

Employment

 Employed full time	129	14.7

 Employed part time	163	18.6

 Student	29	3.3

 Retired	70	8.0

 Not employed	484	55.3

Atypical Medication

 On a atypical medication	628	71.7

	Mean	SD

Age	43.03	11.80

Number of comorbidities	1.27	1.30


Variable	ROSC	No ROSC	P value

Paramedics with prior OHCA case volume ≥ 15 (%)	24.5	22.7	<0.01

Male gender (%)	60.1	63.2	0.01

Non-Caucasian (%)	31.7	29.8	0.09

Age in years (mean, ± SD)	65.7	67.4	<0.01

Shockable rhythm (%)	38.9	21.2	<0.01

Layperson/first responder CPR (%)	51.8	36.3	<0.01

EMS response time in minutes (mean, ± SD)	7.7	8.9	<0.01

Variable

Paramedics with prior OHCA case volume ≥ 15 (%)

Male gender (%)

Non-Caucasian (%)

Age in years (mean, ± SD)

Shockable rhythm (%)

Layperson/first responder CPR (%)

EMS response time in minutes (mean, ± SD)


Component	Score	Definition

Physical Activity

	0	No exercise

	1	1–149 min of moderate exercise or 1–74 min of vigorous exercise/week

	2	150+ minutes of moderate exercise or 75+ minutes of vigorous exercise/week

Dieta

	0	0–1 components of healthy diet

	1	2–3 components of healthy diet

	2	4–5 components of healthy diet

Glucose

	0	≥126 mg/dL fasting

	1	100–125 mg/dL fasting or treated to <100 mg/dL

	2	<100 mg/dL fasting, unmedicated

Blood Pressure

	0	Systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg

	1	Systolic blood pressure 120–139 mmHg or diastolic blood pressure 80–89 mmHg or treated to <120/80 mmHg

	2	<120/80 mmHg, unmedicated

BMI

	0	≥30 kg/m2

	1	25.0–29.99 kg/m2

	2	<25.0 kg/m2

Cholesterol

	0	≥240 mg/dL

	1	200–239 mg/dL or treated to <200 mg/dL

	2	<200 mg/dL, unmedicated

Smoking

	0	Current smoker

	1	Former smoker, quit ≤12 months ago

	2	Never smoker or quit >12 months ago

Component	Score	Definition

	0	≥30 kg/m2

	1	25.0–29.99 kg/m2

	2	<25.0 kg/m2

Cholesterol

	0	≥240 mg/dL

	1	200–239 mg/dL or treated to <200 mg/dL

	2	<200 mg/dL, unmedicated

Smoking

	0	Current smoker

	1	Former smoker, quit ≤12 months ago

	2	Never smoker or quit >12 months ago


Cancer type	Reference

Breast	Fernandez et al. (19), Gazit et al. (20)

Prostate	Daneshmand et al. (23), Fu et al. (24)

Gastric	Song et al. (26)

Ovarian	Huang, LW et al. (25)

Endometrial	Bifulco et al. (31), Calí et al. (32)

Hepatocellular	Su et al. (27); Shuda (28)

Esophageal	Langer et al. (29)

Fibrosarcoma	Jamora et al. (35)

Glioma	Pyrko et al. (34)

Melanoma	Zhuang et al. (33)

Lung	Lin et al. (21), Koomagi et al. (22)

Renal	Fu et al. (30)

Cancer type	Reference

Fibrosarcoma	Jamora et al. (35)

Glioma	Pyrko et al. (34)

Melanoma	Zhuang et al. (33)

Lung	Lin et al. (21), Koomagi et al. (22)

Renal	Fu et al. (30)


LN

 	 	 	CD63

 	 	Number of patients, n (%)	Positive, n	Negative, n	P-value

MDR1	Positive	11 (22.9)	11	0

 	Negative	37 (77.1)	16	21	P < 0.05


Capsules	Spectrophotometric method	Fluorimetric method

Recovery (%) ± SD(a)	F  value(b)	t  value(b)	Recovery (%) ± SD(a)	F  value(b)	t  value(b)

Prozac	99.9 ± 1.4	1.68	1.17	99.7 ± 1.6	2.38	3.00

Pluzac	100.1 ± 1.3	2.62	1.27	99.2 ± 1.5	1.58	2.91

Sa	99.8 ± 1	1		100.8		2.

Capsules	Spectrophotometric method	Fluorimetric method

Recovery (%) ± SD(a)	F  value(b)	t  value(b)	Recovery (%) ± SD(a)	F  value(b)	t  value(b)

lipax	.3	.00	1.10	 ± 1.8	1.60	18

Flutin	100.1 ± 1.6	1.64	1.27	100.1 ± 1.3	0.19	1.12

Octozac	99.8 ± 1.2	2.35	2.13	99.4 ± 1.5	1.49	2.47


	Age (Years)	Height (cm)	Weight (kg)

CFS	43 ± 4.6	164 ± 7.3	73 ± 21.2

Control	43 ± 6.5	167 ± 7.0	70 ± 16.7


	General health	Conditions and symptoms	Infections

‘Type 1’

 1a: Emerging female excess	General health – Past year General health – Past month	High temperature Rash	Eye infection Ear infection

 1b: Increasing female excess		Earache Stomach-ache Headache Lice/scabies	Cold sores Urinary infection

 1c: Disappearing male excess		Breathlessness

‘Type 2’

 2a: Consistent female excess	Health-related days off school	Constipation Eczema	Tonsillitis/laryngitis Cold Worm infections

 2b: Consistent no sex difference		Vomiting Cough Ear discharge Food/drink allergies Non-food/drink allergies	Chicken pox Influenza

 2c: Consistent male excess		Wheezing Asthma Hay fever	Chest infection

‘Type 3’

 3a: Emerging male excess		Pain in arms/legs

 3b: Increasing male excess		Diarrhoea

	General health	Conditions and symptoms	Infections

2c: Consistent male excess		Wheezing Asthma Hay fever	Chest infection

‘Type 3’

3a: Emerging male excess		Pain in arms/legs

3b: Increasing male excess		Diarrhoea


Cross-linked polyurethane	Macrodiols	Diisocyanate	Chain extender	State at room temperature	Tg (°C)	Tm (°C)

CPU 1	PCEG 1	HDI	TMP	Hard	−45	46

CPU 2	PCEG 2	HDI	TMP	Frangibility	−48	44

CPU 3	PCEG 3	HDI	TMP	Elasticity	−51	38

Cross-linked polyurethane	Macrodiols	Diisocyanate	Chain extender	State at room temperature

CPU 1	PCEG 1	HDI	TMP	Hard

CPU 2	PCEG 2	HDI	TMP	Frangibility

CPU 3	PCEG 3	HDI	TMP	Elasticity


Striatal Regionψ	PD (n = 65)	Healthy Controls (n = 27)	F(1,91)	p	Effect size

Normalized Body	0.071% (0.064 – 0.077)	0.078% (0.070 – 0.086)	2.0	0.16	−0.32

Cognitively normal comparison*	PD normal cognition (n = 41)	Healthy Controls (n = 27)	F(1,67)	p	Effect size

Normalized Caudate	0.424% (0.401 – 0.446)	0.470% (0.442 – 0.497)	6.0	0.02	−0.65

Normalized Putamen	0.429% (0.406 – 0.453)	0.465% (0.437 – 0.494)	3.9	0.05	−0.48


	Aerobe genomes	Anaerobe genomes	Facultative genomes

Predictions	Aerobe	137	87	%	Aerobe	6	6	%	Aerobe	43	44	%

Anaerobe	3	2	%	Anaerobe	95	88	%	Anaerobe	21	21	%

Facultative	17	11	%	Facultative	7	6	%	Facultative	34	35	%

Aerobe genomes	Anaerobe genomes	Facultative genomes

Aerobe	137	87	%	Aerobe	6	6	%	Aerobe	43	44	%

Anaerobe	3	2	%	Anaerobe	95	88	%	Anaerobe	21	21	%

Facultative	17	11	%	Facultative	7	6	%	Facultative	34	35	%


Male to female ratio is 432(73%): 160(27%)

Characteristics	Cases (n = 296)	Controls (n = 296)


Annotation type	Content	Elements involved

Curatorial	Meta annotation referring annotations commented on by a curator. Each annotated value can be accepted, rejected and discussed	All elements of the curated annotation

Batch	Meta annotation linking identical annotations referring to different annotated records	All elements of the linked annotation(s)

CuratorialBatch	Meta annotation referring to all curated annotations of a Batch and its annotation type. Each annotated value can be accepted, rejected or commented by the curator for all annotations linked by the referred Batch	All elements of the curated BatchAnnotations


Outcome	Persons with symptomatic RHOA (n = 718), mean (s.d.)

Female, n (%)	442 (62)

Age, years	66.1 (8.1)

BMI, kg/m2	29.3 (5.1)

AUSCAN pain	6.6 (4.2)

AUSCAN stiffness	1.1 (0.9)

AUSCAN function	10.4 (8.1)

AIMS-2 pain subscale	3.8 (2.3)

AIMS-2 hand/finger function	2.2 (2.1)

AIMS-2 impact subscale	2.2 (2.1)

Power grip, lbs	50.7 (25.6)

Pulp pinch, lbs	10.3 (4.1)

GAT	31.8 (12.9)

SF-12 PCS	37.6 (11.8)

SF-12 MCS	50.4 (10.8)

MHQ aesthetics subscale	72.2 (20.5)


Eikelboom morphotypea	Taxonomy	Classification

Phylum	Class	Order	Family	Genus

0092 (30)	RDPb	Chloroflexi	Anaerolineae	Anaerolineales	Anaerolineaceae

Greengenesc	Chloroflexi	Anaerolineae	DRC31

SILVAd	Chloroflexi	Ardenticatenia

MiDASe	Chloroflexi	Ardenticatenia	419	2-1	B45

0803 (27)	RDP	Chloroflexi	Caldilineae	Caldilineales	Caldilineaceae	Caldilinea

Greengenes	Chloroflexi	Anaerolineae	Caldilineales	Caldilineaceae	Caldilinea

SILVA	Chloroflexi	Caldilineae	Caldilineales	Caldilineaceae

MiDAS	Chloroflexi	Caldilineae	Caldilineales	Caldilineaceae	P2CN44

0914 (31)	RDP	Chloroflexi	Caldilineae	Caldilineales	Caldilineaceae

Greengenes	Chloroflexi	Anaerolinea	SHA-20

SILVA	Chloroflexi

MiDAS	Chloroflexi	SJA-15	1-20	1-20	Ca. Sarcinathrix

1851 (28, 32)	RDP	Chloroflexi	Chloroflexia	Chloroflexales	Chloroflexineae	Roseiflexus

Greengenes	Chloroflexi	Chloroflexi	Roseiflexales	Kouleothrixaceae	Kouleothrix

SILVA	Chloroflexi	Chloroflexia	Chloroflexales	Roseiflexaceae	Roseiflexus

MiDAS	Chloroflexi	Chloroflexia	Chloroflexales	Roseiflexaceae	Kouleothrix

Eikelboom morphotypea	Taxonomy	Classification

Phylum	Class	Order

0092 (30)	RDPb	Chloroflexi	Anaerolineae	Anaerolineales

Greengenesc	Chloroflexi	Anaerolineae	DRC31

SILVAd	Chloroflexi	Ardenticatenia

MiDASe	Chloroflexi	Ardenticatenia	419

0803 (27)	RDP	Chloroflexi	Caldilineae	Caldilineales

Greengenes	Chloroflexi	Anaerolineae	Caldilineales

SILVA	Chloroflexi	Caldilineae	Caldilineales

MiDAS	Chloroflexi	Caldilineae	Caldilineales

0914 (31)	RDP	Chloroflexi	Caldilineae	Caldilineales

Greengenes	Chloroflexi	Anaerolinea	SHA-20

SILVA	Chloroflexi

MiDAS	Chloroflexi	SJA-15	1-20

1851 (28, 32)	RDP	Chloroflexi	Chloroflexia	Chloroflexales

Greengenes	Chloroflexi	Chloroflexi	Roseiflexales

SILVA	Chloroflexi	Chloroflexia	Chloroflexales

MiDAS	Chloroflexi	Chloroflexia	Chloroflexales

Classification

Family	Genus

Anaerolineaceae

2-1	B45

Caldilineaceae	Caldilinea

Caldilineaceae	Caldilinea

Caldilineaceae

Caldilineaceae	P2CN44

Caldilineaceae

1-20	Ca. Sarcinathrix

Chloroflexineae	Roseiflexus

Kouleothrixaceae	Kouleothrix

Roseiflexaceae	Roseiflexus

Roseiflexaceae	Kouleothrix


Variables	Codes

−1	0	+1

Frying temperature (°C)	140	150	160

Frying time (min)	2	3	4

Level of BSCF (%)	20	30	40

Thickness (mm)	2	3	4

Variables	Codes

−1

Frying temperature (°C)	140

Frying time (min)	2

Level of BSCF (%)	20

Thickness (mm)	2


Material	Element type	Constitutive relation	Material properties

Bony structures

Vertebral cortical bone, endplates, and posterior cortical bone	8 Nodes brick element (C3D8)	Isotropic, elastic	E = 12,000 MPa ν = 0.3

Vertebral cancellous bone and posterior cancellous bone	8 Nodes brick element (C3D8)	Isotropic, elastic	E = 100 MPa ν = 0.2

Ligaments			Elastic modulus MPa (strain %)

Anterior longitudinal	Tension-only, truss elements (T3D2)	Hypoelastic	7.8 (<12%), 20.0 (>12%) ν = 0.3

Posterior longitudinal	Tension-only, truss elements (T3D2)	Hypoelastic	10.0 (<11%), 20.0 (>11%) ν = 0.3

Ligamentum flavum	Tension-only, truss elements (T3D2)	Hypoelastic	15.0 (<6.2%), 19.5 (>6.2%) ν = 0.3

Intertransverse	Tension-only, truss elements (T3D2)	Hypoelastic	10.0 (<18%), 58.7 (>18%) ν = 0.3

Interspinous	Tension-only, truss elements (T3D2)	Hypoelastic	10.0 (<14%), 11.6 (>14%) ν = 0.3

Supraspinous	Tension-only, truss elements (T3D2)	Hypoelastic	8.0 (<20%), 15.0 (>20%) ν = 0.3

Capsular	Tension-only, truss elements (T3D2)	Hypoelastic	7.5 (<25%), 32.9 (>25%) ν = 0.3

Intervertebral disk

Nucleus pulposus	8 Nodes brick element (C3D8)	Isotropic, elastic	E = 2 MPa ν = 0.499

Annulus fibrosus	8 Nodes brick element (C3D8)	Hyperelastic anisotropic (HGO)	Table 2

Apophyseal joints	GAPUNI elements	Non-linear soft contact	Pressure overclosure = 12,000 MPa


	Men	Women

	Model 0	Model 1	Model 2	Model 0	Model 1	Model 2	Model 3b

	OR		OR		OR		OR		OR		OR		OR

Intercept	0.21	***	0.07	***	0.07	***	0.18	***	0.08	***	0.09	***	0.09	***

(1) Individual variablesa

Education Level (ref. University Studies)


	LFI strip test	DAS ELISA (OD)

Pig 77	Swap 1	+	1.717

Swap 2	+	1.3

Swap 3	+	0.307

Pig 78	Swap 1	+	0.604

Pig 79	Swap 1	+	1.589


Causes of pulmonary hypertension in ICU	Causes of RV failure in ICU

1) PAH (for example, preexisting PAH; PoPH (8.5% ESLD)	1) RV Pressure overload, pulmonary hypertension, any cause

2) Elevated LAP: RV pressure overload (left-sided myocardial infarction/cardiomyopathy; mitral regurgitation; pulmonary stenosis)	2) Reduced RV contractility

3) PH due to hypoxia: acute (for example, ARDS)/preexisting lung disease (for example, COPD, IPF)	 RV infarction; sepsis; RV cardiomyopathy; myocarditis; pericardial disease; LVAD; after CPB; after cardiac surgery/transplantation

4) Thromboembolic (for example, acute PE; chronic (CTEPH); other causes of emboli (AFE, air, cement)	3) RV-volume overload

5) Mechanical (for example, increased Pplat - IPPV	 Cardiac causes: tricuspid and pulmonary regurgitation; intracardiac shunts


Gene	5′–3′ sequence

P5CS1	F‐GTAGACGACGACGACGATAATG

R‐ACTGCTGTCCCAACCTTAAC

P5CS2	F‐GGTGCTGAGGTGGGAATAAG

R‐ACTTGTCCCTTTCCTCTCATTATC

P5CR	F‐GAGGAGTAGCTGCTGGTTTAC

R‐CCTGGATGCTTCCCAGTTT

OAT	F‐TGCTTGAGCTTGAAGGAGAG

R‐GATCCATCTCGGAGTTCATCAG

PDH1	F‐AGCAGCTCATGGAAGGATTC

R‐GGGTTGGAGGATTGTGTCTT

PDH2	F‐GCGTAGAACACGCTGAAGA

R‐GCTTAAGTGAGACGAAGGTAGG

P5CDH	F‐AGGATGCACGCTCATCTAAC

R‐CCAGCATATGTAGTCCCATTCA

GAPDH	F‐TTGTTGTTGAGTCCACTG

R‐CTTGTATTCCTTCTCGTTGA

Gene

P5CS1

P5CS2

P5CR

OAT

PDH1

PDH2

P5CDH

GAPDH

5′–3′ sequence

F‐GTAGACGACGACGACGATAATG

R‐ACTGCTGTCCCAACCTTAAC

F‐GGTGCTGAGGTGGGAATAAG

R‐ACTTGTCCCTTTCCTCTCATTATC

F‐GAGGAGTAGCTGCTGGTTTAC

R‐CCTGGATGCTTCCCAGTTT

F‐TGCTTGAGCTTGAAGGAGAG

R‐GATCCATCTCGGAGTTCATCAG

F‐AGCAGCTCATGGAAGGATTC

R‐GGGTTGGAGGATTGTGTCTT

F‐GCGTAGAACACGCTGAAGA

R‐GCTTAAGTGAGACGAAGGTAGG

F‐AGGATGCACGCTCATCTAAC

R‐CCAGCATATGTAGTCCCATTCA

F‐TTGTTGTTGAGTCCACTG

R‐CTTGTATTCCTTCTCGTTGA


Author	Country	Year	Type of study	Patients	Control	Cut off (pmol/L)	TP	FP	FN	TN	SEN	SPE

Moore RG et al. [5]	USA	2008	prospective/retrospective	171	156	/	78	8	93	148	46	95

Zanotti L et al. [6]	Italy	2012	retrospective	193(152 + 41)	125	51	152	19	41	106	79	85

 	 	 	 	 	 	64	127	6	66	119	66	95

Angioli R et al. [7]	Italy	2013	prospective	101(95 + 6)	103	70	60	0	41	103	59	100

 	 	 	 	 	 	150	36	0	65	103	36	100

Omer Bet al. [8]	Turkey	2013	prospective l	64(54 + 10)	94(60 + 34)	60	48	32	16	62	75	66

Bignotti E et al. [9]	Italy	2011	prospective	138(109 + 29)	76	/	92	4	46	72	67	95

Zhang, Ai-min et al. [10]	China	2012	prospective	124	206(97 + 109)	/	51	10	73	196	41	95

Total	 	 	 	791	760

Author	Country	Year	Type of study	Patients	Control	Cut off (pmol/L)	TP	FP	FN	TN	SEN	SPE

						64	127	6	66	119	66	95

Angioli R et al. [7]	Italy	2013	prospective	101(95 + 6)	103	70	60	0	41	103	59	100

						150	36	0	65	103	36	100

Omer Bet al. [8]	Turkey	2013	prospective l	64(54 + 10)	94(60 + 34)	60	48	32	16	62	75	66

Bignotti E et al. [9]	Italy	2011	prospective	138(109 + 29)	76	/	92	4	46	72	67	95

Zhang, Ai-min et al. [10]	China	2012	prospective	124	206(97 + 109)	/	51	10	73	196	41	95

Total				791	760


Training description	Related themes

1. Video: Invite for the workshop and foundational information on Rx for Change and systematic reviews<underline>Delivery:</underline> A video (prezi with audio narration) covering general information about Rx for Change and systematic reviews; the video was sent electronically 1 week prior to the workshop with a request for people to review it prior to attending the workshop; duration was 6 minutes<underline>Content:</underline> Quick facts about the database, information on the type of evidence included, information on when it can be used and how it can help participants in their work; an invitation to attend a free workshop and to explore Rx for Change on-line in a group environment was included	Need for knowledgeDiversity in delivery

2. Face-to-face workshop (1 hour)<underline>Delivery:</underline> Didactic presentation (15 min) + hands on skills training (45 min) + discussion (15 min) + handouts<underline>Content of didactic presentation</underline>: Rx for Change was presented as part of the evidence source “puzzle” Knowledge users’ questions (as per interviews) partly guided the session’s themes (e.g. What is Rx for Change? Can I trust the evidence presented? What types of questions are relevant? How is Rx for Change different compared to other evidence sources?); the didactic part of the session focused on emphasizing “How we turn a research question into a “searchable question” in the Rx for Change database”<underline>Content of hands-on skills training</underline>: A pre-determined example of a research question was used to demonstrate and familiarise participants with strategic navigation strategies for the Rx for Change database; screenshots were used along with an audio or live presentation/demonstration; the three-question framework based on Lavis et al. [21] was used to demonstrate different ways of searching efficiently, the layout of the database, the taxonomy and the layers of the database Participants were then asked to use one of their own work examples and search the database based on the same three-question framework; this was a facilitated exerciseThe session was facilitated by a research team member with expertise in Rx for Change or an external collaborator with knowledge of Rx for Change<underline>Content of discussion:</underline> The incorporation and applicability of the evidence in one’s context as well as the strengths and limitations of the database and the evidence that it includes was discussed<underline>Handouts:</underline> Frequently Asked Questions and a “map” of the database layout (screenshots) were given to participants in the form of handouts after the session (for desk use)	Didactic presentation: Need for knowledgeHands on skills training: Need for skill development in navigating the database and integrating evidence into decision-making, tailoringDiscussion: Knowledge and skillsHandouts: Need for knowledge, variety in delivery methods

3. Post-training remindersDelivery: Emailed at 1 and 3 months post-workshopContent: Cues and/or reminders regarding the database’s use, value, updates, and navigation tips	Routine habits

Training description	Related themes

1. Video: Invite for the workshop and foundational information on Rx for Change and systematic reviewsDelivery: A video (prezi with audio narration) covering general information about Rx for Change and systematic reviews; the video was sent electronically 1 week prior to the workshop with a request for people to review it prior to attending the workshop; duration was 6 minutesContent: Quick facts about the database, information on the type of evidence included, information on when it can be used and how it can help participants in their work; an invitation to attend a free workshop and to explore Rx for Change on-line in a group environment was included	Need for knowledgeDiversity in delivery

2. Face-to-face workshop (1 hour)Delivery: Didactic presentation (15 min) + hands on skills training (45 min) + discussion (15 min) + handoutsContent of didactic presentation: Rx for Change was presented as part of the evidence source “puzzle” Knowledge users’ questions (as per interviews) partly guided the session’s themes (e.g. What is Rx for Change? Can I trust the evidence presented? What types of questions are relevant? How is Rx for Change different compared to other evidence sources?); the didactic part of the session focused on emphasizing “How we turn a research question into a “searchable question” in the Rx for Change database”Content of hands-on skills training: A pre-determined example of a research question was used to demonstrate and familiarise participants with strategic navigation strategies for the Rx for Change database; screenshots were used along with an audio or live presentation/demonstration; the three-question framework based on Lavis et al. [21] was used to demonstrate different ways of searching efficiently, the layout of the database, the taxonomy and the layers of the database Participants were then asked to use one of their own work examples and search the database based on the same three-question framework; this was a facilitated exerciseThe session was facilitated by a research team member with expertise in Rx for Change or an external collaborator with knowledge of Rx for ChangeContent of discussion: The incorporation and applicability of the evidence in one’s context as well as the strengths and limitations of the database and the evidence that it includes was discussedHandouts: Frequently Asked Questions and a “map” of the database layout (screenshots) were given to participants in the form of handouts after the session (for desk use)	Didactic presentation: Need for knowledgeHands on skills training: Need for skill development in navigating the database and integrating evidence into decision-making, tailoringDiscussion: Knowledge and skillsHandouts: Need for knowledge, variety in delivery methods


Motif	Number of matches

P. pastoris AT-ACS	15

P. pastoris GC-ACS	1

S. cerevisiae 11 bp ACS	11

S. cerevisiae 17 bp ACS	6

Motif	Number of matches

S. cerevisiae 17 bp ACS	6


Characteristic	Overall

N

N	14,651

Age in years (median & IQR)	69

Female	8317

Residential care	433

Deprived home locationa	1215

Rural home location	4014

Emergency hospital admission	8689

Medical specialty admission	7203

Critical care admission	1288

Intensive care admission	428

Length of hospital stay in days (median & IQR)	3

Cancer	1011

Cardiac failure	668

Cerebrovascular disease	613

Dementia	150

Diabetes	917

Liver disease	189

Myocardial infarction	735

Neurologic disease	76

Peptic disease	304

Peripheral vascular disease	487

Pulmonary disease	836

Rheumatic disease	312

Baseline (pre-episode) eGFR (median & IQR)	66.8

Post-episode eGFRb

≥60	9004

45–59	3369

30–44	1733

<30	545

Intra-episode background change in eGFRc

>30% rise	1135

10%–30% rise	2069

No change	7654

10%–30% fall	2990

>30% fall	803

Post-episode proteinuriad

Untested	13069

Normal	753

Abnormal	829

AKI stage

0	12685

1	1355

2	410

3	201

Prior AKI episodes	1358


Driers	Appearance	Odor	Taste	Flavor	Texture	Palability	Acceptability	Shelf-life (1–30 days)

Plastic	Attractive	Pleasant	Fair	Fair	Hard	Good	Moderate	Long

Mosquito net	Attractive	Pleasant	Good	Good	Very hard	Good	High	Long

Glass	Very attractive	Pleasant	Very good	Very good	Very hard	Good	Very high	Longer

Aluminum	Attractive	Pleasant	Good	Good	Very hard	Good	High	Longer

Glass with black stone	Very attractive	Very pleasant	Very good	Very good	Very hard	Very good	Very high	Longest

Open-sun drying (control)	Not attractive	Not pleasant	Fair	Fair	Hard	Fair	Low	Not long

Driers	Appearance	Odor	Taste	Flavor	Texture	Palability	Acceptability	Shelf-life (1–30 days)

Glass with black stone	Very attractive	Very pleasant	Very good	Very good	Very hard	Very good	Very high	Longest

Open-sun drying (control)	Not attractive	Not pleasant	Fair	Fair	Hard	Fair	Low	Not long


Opioids	Crystalloid	Colloid	P value

Fentanyl (mcg)	25 (0.0–100)	25 (0.0–75.0)	0.52

Pethidine (mg)	10.3 (23.7)	4.9 (16.2)	0.17

Rescue Anti-emetics

Number of Patients Requiring Rescue

Anti-emetics N(%)	9 (16.9)	5 (5.3)	0.37

Time of Anti-emetic administration. N (%)

0–30 min	2 (3.6)	3 (5.3)	0.98

30 min–2 hrs	5 (9.1)	2 (3.5)	0.42

2–24 hrs	3 (5.7)	0 (0.0)	0.22


Sl. no	Hydrophobic substrates	Emulsification index (%)

24 h	168 h

1		2	22.58 ± 0.1

Sl. no	Hydrophobic substrates	Emulsification index (%)

24 h	168 h

	n-Hexadecane	5.19 ± 0.12	1

2	Sunflower oil	33.33 ± 0.87	5.26 ± 0.53

3	Motor oil	62.26 ± 0.32	60.00 ± 0.12

4	Diesel	25.00 ± 0.25	5.00 ± 0.43

5	Crude oil	100.00 ± 0.32	83.33 ± 0.23


Procedure	Number

Abdominal aortic aneurysm repair	1

Abdominoperineal resection	1

Atrial septal defect closure	2

Bronchoscopy	1

Coronary artery bypass grafting	2

Cardiac ablation	1

Cardiac catheterization	3

Inadvertent air bolus via IV line	1

Central vascular access	9

Endoscopic Retrograde Cholangio-Pancreatography (ERCP)	1

Hysteroscopy	1

Laparoscopic liver resection	2

Necrotic bowel resection	1

Endovascular neurointervention	2

Neurosurgery (open procedures)	11

Pacemaker placement	1

Spinal surgery	2

Transarterial chemoembolization (TACE)	1

Cardiac valve replacement	4

Varicose vein injection	2

Procedure	Number

Transarterial chemoembolization (TACE)	1

Cardiac valve replacement	4

Varicose vein injection	2